Published in final edited form as:

J Pharm Sci. 2011 September ; 100(9): 3636–3654. doi:10.1002/jps.22655.

Influence of Drug Transport Proteins on Pharmacokinetics and Drug Interactions of HIV Protease Inhibitors

LaToya Griffin,

University of North Carolina at Chapel Hill, Eshelman School of Pharmacy, Division of Pharmacotherapy and Experimental Therapeutics

Pieter Annaert, and

KULeuven, Pharmaceutical Sciences, Lab, Pharmacotechnology and Biopharmacy

Kim Brouwer

University of North Carolina at Chapel Hill, Eshelman School of Pharmacy, Division of Pharmacotherapy and Experimental Therapeutics

I. Introduction

Saquinavir was the first protease inhibitor introduced to the U.S. market in 1995 for the treatment of HIV/AIDS.¹ This class of life-saving antiretroviral agents has expanded to now include eight protease inhibitors that play an important role in the management of HIV infection.² Currently, the most frequently prescribed HIV protease inhibitors include lopinavir, atazanavir, darunavir and fosamprenavir, each of which is typically used in combination with one or more Nucleoside Reverse Transcriptase Inhibitor (NRTI) in Highly Active Antiretroviral Therapy (HAART) regimens.³ In addition, more recent clinical data support the potential utility of HIV PI monotherapy in patients with prolonged viral suppression on HAART,⁴ further illustrating the unique efficacy profile of these antiretroviral agents. The spectacular improvements in treatment success and life expectancy in patients with HIV infection can be attributed, in part, to the long-term suppression of HIV replication by antiretroviral regimens with acceptable side-effect profiles.⁵ HIV protease inhibitors currently are key components of first-line therapy in both treatment-naïve and -experienced patients. A major challenge in antiretroviral pharmacotherapy is the potential for gradual development of viral resistance. The introduction of 2nd generation protease inhibitors such as darunavir, which require at least four concomitant mutations in the viral genome for resistance development, has provided clinicians with superior drugs to counter the development of resistance.⁶

Physicochemical properties of the HIV protease inhibitors are summarized in Table 1. In general, HIV protease inhibitors are peptidomimetic, large molecular weight, and often poorly water soluble compounds. Consistent with their physicochemical properties, HIV protease inhibitors tend to be highly protein bound and extensively metabolized by cytochrome P450 (CYP) 3A4 (Table 2), with relatively short terminal elimination half-lives in plasma. Long-term therapeutic success can be maintained only when minimum trough concentrations of the HIV protease inhibitors are achieved.⁴ Rapid elimination from plasma requires multiple daily doses of HIV protease inhibitors to maintain therapeutic concentrations, which complicates patient adherence to therapy. Ritonavir is a remarkably potent mechanism-based inhibitor of CYP3A4. Concomitant administration of a

*To whom correspondence should be addressed: Kim L.R. Brouwer (Telephone: + 919-962-7030; Fax: +919-962-0644; kbrouwer@unc.edu.

subtherapeutic dose (100-200 mg) of ritonavir as a pharmacokinetic booster (“enhancer”) together with HIV protease inhibitors increases exposure of lopinavir, atazanavir and darunavir several-fold.⁷ The use of ritonavir as a “boosting” agent was a major advance in HIV protease inhibitor-based therapy,^{8,9} and has led to the development and marketing of once-daily dosage forms of HIV protease inhibitors, which has increased significantly patient adherence. In addition, the clinical use of ritonavir-boosted HIV protease inhibitors has improved the side-effect and toxicity profile of HAART regimens.¹⁰ For example, the addition of ritonavir to atazanavir-based dosing regimens resulted in decreased incidence of lipatrophy as compared to unboosted treatments.¹¹

Although the clinical strategy of using ritonavir as a boosting agent has enhanced the success of HIV protease inhibitor-based antiretroviral regimens, it also has resulted in increased potential for drug-drug interactions (DDIs).¹² Drugs metabolized by CYP3A4 exhibit much longer elimination half-lives in ritonavir-treated patients as compared to other patients. Additional levels of complexity with respect to DDI potential are encountered in patients co-infected with *M. tuberculosis*, an infection that is increasing in prevalence in resource-limited countries.¹³ Successful eradication of tuberculosis almost always requires administration of the very potent CYP3A4-inducer rifampicin, or the less potent but more expensive inducer rifabutin. These drugs reduce exposure to ritonavir-boosted HIV protease inhibitors.

This manuscript provides an updated review of the influence of drug transport proteins on the pharmacokinetics and DDIs of this important class of antiretroviral agents. Clearly, hepatic metabolism is an important step in the systemic elimination of HIV protease inhibitors. Drug transporters also play a key role in the oral bioavailability, hepatobiliary elimination and distribution of HIV protease inhibitors to target (lymphocytes) and peripheral (brain) tissues. ADME-relevant proteins that influence the pharmacokinetics of HIV protease inhibitors are discussed in section II. A critical review of the most important, clinically relevant DDIs involving HIV protease inhibitors is discussed in Section III. Sections IV and V focus on the role of transporters in mechanisms underlying side-effects associated with HIV protease inhibitors, and on the influence of HIV infection and disease on transporter expression and function, respectively. The recent approval of protease inhibitors for the treatment of hepatitis C has increased the number of patients who are exposed to this class of drugs, and emphasizes the importance of understanding factors that influence their pharmacokinetics and DDI potential.

II. The Impact of Transporters on Protease Inhibitor Pharmacokinetics/Pharmacodynamics

Pharmacological and toxicological effects of protease inhibitors are determined by drug absorption and distribution which are influenced by transporter-mediated processes. Thus, identifying transport proteins that interact with protease inhibitors and understanding the magnitude of their contribution to overall drug disposition is critical. Although protease inhibitors are known to inhibit active transport processes, data regarding the ability of protease inhibitors, themselves, to act as substrates for uptake proteins remains controversial. Significant temperature-dependent uptake of ritonavir, saquinavir and nelfinavir into suspended rat hepatocytes, indicative of active uptake processes, has been reported.¹⁴ In addition to evidence provided by limited *in vitro* studies, the physicochemical properties of protease inhibitors (e.g., molecular size, protein binding, lipophilicity) (see Table 1) also should be considered. Localization and orientation of membrane transporters in a generalized cell is illustrated in Figure 1. Transporters have been well characterized in the liver, kidney and, to a lesser extent, the brain and intestine. Unfortunately, one challenge in the field is that the expression, localization and functional activity of transport proteins at

target sites for viral transmission and sequestration, including the testicular system, female genital tract, lymphocytes and placenta are poorly characterized. However, this lapse in scientific knowledge is appreciated and studies in this area are ongoing. For an in depth discussion of the interactions between antiretroviral agents and transporters at these relevant organ systems see Kis et al, 2010.¹⁵ The following discussion serves as an overview of solute carrier (SLCO) and ATP-binding cassette (ABC) membrane transport proteins involved in the uptake and efflux of protease inhibitors known to date.

A. Impact of SLCO Transporters on Protease Inhibitor Pharmacokinetics/ Pharmacodynamics

Transporter-mediated uptake, largely governed by members of the SLCO superfamily, may be rate limiting in the oral bioavailability and hepatobiliary clearance of drugs. The most prominent transporter interactions with protease inhibitors involve the organic anion transporting polypeptides (OATPs) and organic cation transporters (OCTs); the clinical relevance of these interactions has been well documented.

OATPs—OATPs, which are expressed in numerous organs and tissues including the intestine, liver, kidney, and placenta, mediate the sodium-independent bidirectional transport of diverse substrates including bile acids, bilirubin and xenobiotics.^{16,17} OATPs interact with several protease inhibitors *in vitro*. OATP1A2, -1B1 and -1B3 expressed in *Xenopus laevis* oocytes mediate the uptake of lopinavir and saquinavir.¹⁸⁻²⁰ Darunavir transport via OATP1A2- and -1B1- also has been reported.^{19,20} Lopinavir, atazanavir, darunavir, ritonavir and saquinavir inhibit OATP1B1- and -1B3-mediated CGamF accumulation in chinese hamster ovary (CHO) cells. Inhibition of OATP2B1-mediated transport of estrone 3-sulfate by atazanavir, lopinavir, tipranavir, nelfinavir, indinavir, saquinavir, and ritonavir also has been shown in Caco-2 cells.^{21,22} The clinical implications of these interactions are evident, for example, in the significant association between OATP1B1 521T>C polymorphisms and elevated lopinavir plasma concentrations.¹⁹ Additionally, a recent pharmacogenetics study revealed that variability in lopinavir clearance was impacted by both genetic variants in OATP1B1 and ritonavir plasma concentrations.²³

OCTs—OCTs, which are located predominantly in the kidneys and liver, are electrogenic uniporters that primarily transport small cations in a sodium-independent manner. Transport of uncharged and anionic compounds such as prostaglandins by OCTs has been described.²⁴ OCT1 and OCT3 are expressed at the sinusoidal membrane of liver tissue. OCT1 is expressed exclusively in the liver while OCT3 has a broader range of tissue distribution. Nelfinavir, ritonavir, indinavir, and saquinavir are reportedly potent inhibitors, but poor substrates, of OCT1- and OCT2-mediated transport.^{25,26} Though the contribution of OCTs to protease inhibitor transport remains unclear, several nucleoside NRTIs are translocated by OCTs and often are co-administered with protease inhibitors, increasing the risk of DDIs.

B. The Impact of ABC Transporters on Protease Inhibitor Pharmacokinetics/ Pharmacodynamics

Members of the ABC transporter superfamily comprise one of the largest protein families with representatives in all living organisms. The structure and function of ABC transporters are relatively conserved across species. ABC transporters facilitate the transmembrane movement of substrates by utilizing the energy generated by ATP hydrolysis.²⁷ Mounting evidence suggests that ABC transport proteins confer drug resistance and alter protease inhibitor pharmacokinetics/pharmacodynamics by decreasing bioavailability, promoting sequestration at sanctuary sites, and decreasing accumulation in target organs and tissues.²⁸ This review focuses solely on ABC transporters clinically shown to impact the disposition of protease inhibitors.

P-gp—P-glycoprotein (P-gp; MDR1), which is expressed ubiquitously, protects cells from the accumulation of toxic drugs, metabolites, and endogenous compounds. P-gp exhibits broad substrate specificity, including protease inhibitors. Expression of P-gp in the intestine, brain and blood-testis barrier alters oral bioavailability and intracellular concentrations of protease inhibitors *in vivo*.²⁹⁻³¹ P-gp-mediated efflux of all currently marketed protease inhibitors has been demonstrated in several *in vitro* systems, including Caco-2 and MDCK-II cells.³²⁻³⁶ Ritonavir, lopinavir and nelfinavir also inhibit P-gp-dependent efflux of calcein-AM in MDCK-II cells.³⁷ In addition to inhibition of P-gp transport, saquinavir and darunavir induce P-gp mRNA expression and activity *in vitro*. Induction by darunavir increased cellular resistance, as measured by growth inhibition assays in LS-180 cell lines.³⁸

BCRP—Breast cancer resistance protein (BCRP) is expressed in the liver, kidney, testis, GI tract and a many other tissues. BCRP is responsible for the extrusion of a broad range of both endogenous and exogenous compounds. Many protease inhibitors including lopinavir, nelfinavir, saquinavir, and ritonavir are effective inhibitors of BCRP-mediated transport, but appear to be poor substrates *in vitro*.³⁹⁻⁴¹ Although BCRP-mediated transport of protease inhibitors has not been elucidated, BCRP activity is known to alter systemic and tissue concentrations of an antiretroviral and in particular, protease inhibitors.⁴² Consequently, the likelihood of DDIs between protease inhibitors and BCRP substrates remains a concern.

MRPs—To date, there are nine members of the multi-drug resistance-associated protein (MRP) transporter family. MRPs 1-5, all organic anion pumps, have been studied most extensively. MRP1 and MRP2 have similar substrate specificities; however, localization and tissue distribution differ. MRP1 is expressed widely and located in the basolateral membrane, while MRP2 is localized on the apical membrane and expression is restricted primarily to the liver, kidney, and intestine. MRP3 is expressed on the basolateral membrane of the liver, kidney and gastrointestinal tract.^{29,43} Common MRP1, MRP2 and MRP4 substrates include glutathione conjugates and anionic drugs. Bilirubin glucuronide is a substrate for both MRP2 and MRP3.^{44,45} MRP2-mediated transport of saquinavir, ritonavir, indinavir and lopinavir has been shown in stably transfected human MDCK-II cells.^{32,46} Saquinavir, ritonavir and atazanavir potently inhibit MRP2-mediated biliary efflux of CDF in human hepatocytes.⁴⁷ In a panel of ABC transporter over-expressing cell lines, atazanavir, lopinavir and ritonavir inhibited MRP1 activity.³⁹ Furthermore, treatment with darunavir/ritonavir induced MRP1 protein expression in CD4 (+) T-cells from healthy human volunteers. MRP1-mediated efflux of carboxyfluorescein diacetate increased upon co-administration with efavirenz.⁴⁸ The contribution of MRPs to the transport of protease inhibitors remains unclear.

III. Drug-Drug Interactions Involving Transporters and HIV Protease Inhibitors

Numerous *in vitro* and *in vivo* studies have demonstrated that most HIV protease inhibitors interact with both CYP3A4 and P-gp, either as a substrate, inhibitor or inducer.^{8,49,50} Given the dominant roles of these proteins in drug disposition, most clinical DDI studies have focused on the contribution of CYP3A4 and/or P-gp.⁸ In addition to the CYP3A4-mediated inhibition of protease inhibitors by ritonavir, a beneficial DDI that is utilized chemically in HAART regimens, synergistic effects have been observed with other combination of HIV protease inhibitors. Dam and co-workers suggested that the synergistic inhibition of HIV-1 by a combination of saquinavir with lopinavir or atazanavir could be explained, at least in part, by enhanced inhibition of efflux mechanisms from target cells.⁵¹ The complexity of HIV protease inhibitor-based treatment regimens, often in combination with non-

antiretroviral medication (e.g. anti-tuberculosis drugs), increases the potential for clinically significant DDIs (see www.hiv-druginteractions.org for a summary of risks and severity of antiretroviral DDIs). Unfortunately, details regarding the underlying mechanisms responsible for these DDIs are lacking, but clearly extend far beyond the involvement of CYP3A4 and P-gp. Clinically relevant changes in protease inhibitor concentrations often may be the net result of multiple DDIs that have opposite effects (e.g. concomitant induction and inhibition); the outcome frequently depends on the exact dose and regimens (e.g. etravirine and darunavir/ritonavir in Table 4).⁵² Another reason for the lack of mechanistic information is that the relative roles of drug metabolizing enzymes and transporters in drug disposition and DDIs remain poorly understood. Table 4 provides a summary of clinically relevant DDIs involving HIV protease inhibitors and drug transporters; specific DDIs involving HIV protease inhibitors as ‘victim’ drugs (Table 4A), and those mediated by HIV protease inhibitors as ‘perpetrator’ drugs (Table 4B), are discussed below.

III.1. Mechanisms of HIV Protease Inhibitor DDIs: Drug Transporter Inhibition

As summarized in Table 3, HIV protease inhibitors are both substrates and potent inhibitors of some SLCO and ABC transport proteins, and typically behave as perpetrators when considering DDIs elicited by transporter inhibition. In addition, when more than two HIV protease inhibitors are combined, different protease inhibitors can act as the perpetrator and victim. This is illustrated by the effect of atazanavir on the pharmacokinetics of saquinavir when coadministered with ritonavir (see Table 4C).⁵³ Saturation and/or inhibition of efflux transporters modulating HIV protease inhibitor accumulation may explain this interaction.

The most well documented DDIs with respect to transporter inhibition involve HIV protease inhibitors and the disposition of well-known P-gp substrates including digoxin, fexofenadine and loperamide (see Table 4B). For example, single or multiple dose regimens with indinavir/ritonavir increased fexofenadine plasma AUC up to 5- and 4.2-fold, respectively.⁵⁴ The most pronounced effects on digoxin exposure were reported after 300 mg bid ritonavir or 400/100 mg lopinavir/ritonavir in combination with intravenous or oral digoxin doses of 0.5 mg.⁵⁵ Loperamide exposure was increased more than 3-fold in the presence of 600 mg ritonavir.⁵⁶ Case reports of elevated tacrolimus or sirolimus concentrations when combined with ritonavir-boosted amprenavir or darunavir also support pronounced P-gp inhibition.^{57,58} HIV protease inhibitors appear to exhibit much less pronounced (up to 37% increase) effects on the plasma exposure of the NRTI and P-gp substrate tenofovir following co-administration of the disoproxil fumarate prodrug of tenofovir.⁵⁹ Minor increases in tenofovir plasma AUC values were observed (see Table 4B), which were attributed to inhibition of P-gp mediated intestinal efflux of the prodrug.^{59,60}

Compared to ABC transporter-based DDIs, much less is known about the potential role of HIV protease inhibitors in DDIs associated with uptake transporters. Limited data suggest that hepatic uptake transporters of the *SLCO* family (specifically OATP1B1 and OATP1B3) are likely to play key roles in some DDIs involving HIV protease inhibitors. Shitara recently reviewed current clinical evidence demonstrating substantial alterations in the pharmacokinetics of OATP1B1 substrates (i.e. statins, repaglinide and bosentan) in combination with the OATP1B1 inhibitor cyclosporin A. These data revealed increases in the AUC of atorvastatin of up to 9-fold.⁶¹ Pronounced increases in the AUC of the lipid-lowering drugs atorvastatin and rosuvastatin have been reported with coadministration of boosted lopinavir and tipranavir; OATP1B1 inhibition has been suggested as a likely mechanism to explain this interaction.⁶² Moderately decreased exposure to the NRTI elvucitabine when combined with a single 300 mg ritonavir dose may be attributed to ritonavir-mediated inhibition of the intestinal uptake transporter.⁶³

Finally, it is noteworthy that even though pronounced species differences exist,⁴⁷ several animal studies also support the role of transporters in mediating DDIs involving HIV protease inhibitors. For example, ritonavir enhanced darunavir absorption via P-gp inhibition in mouse *in situ* intestinal perfusions.⁶⁴

III.2. Mechanisms of HIV Protease Inhibitor DDIs: Drug Transporter Induction

Data obtained in various *in vitro* models have shown that HIV protease inhibitors show affinity for the orphan nuclear receptor hPXR, activation of which is clearly linked to regulation of drug metabolizing enzymes as well as drug transporter expression.^{65,66} Induction of drug metabolizing enzymes by HIV protease inhibitors is a common mechanism underlying clinically relevant protease inhibitor-associated DDIs.^{67,68} Much less information is available with respect to the exact role of altered expression of drug transporters and changes in the pharmacokinetics of co-administered drugs relying on those drug transporters. Nevertheless, numerous examples in Table 5 illustrate that most drug transporters are susceptible to the inducing effects of HIV protease inhibitors. Clinically relevant DDIs that may be attributed, at least in part, to HIV protease inhibitor-mediated up-regulation of P-gp activity are included in Table 4B. For example, there is a 2-3-fold decrease in loperamide exposure when combined with tipranavir/ritonavir.⁶⁹ The latter protease inhibitor combination also significantly reduced exposure to the P-gp substrate digoxin, presumably through induction of P-gp, following concomitant doses of TPV/r.⁷⁰ It should be noted that the inducing effects of TPV predominate in contrast to ritonavir, which primarily inhibits P-gp when combined with loperamide or digoxin. The 25% reductions in fexofenadine C_{max} and half-life (Table 4.B) when combined with nelfinavir for 1 week, may be explained by induction of intestinal P-gp and/or hepatic OATPs.⁷¹ The reduced exposure to delaviridine also could be due to induction of P-gp by amprenavir.⁷² The NNRTI efavirenz can be combined with several boosted protease inhibitors, including darunavir, lopinavir and saquinavir;⁷³ however, when combined with tipranavir/ritonavir, the plasma exposure of efavirenz is decreased by 76% (Table 4.B). As efavirenz is not a P-gp, BCRP or MRP substrate,^{74,75} induction of uptake transporters (e.g. OATPs) by tipranavir and/or ritonavir (in addition to induction of drug metabolizing enzymes) may contribute to this interaction.

Combined use of rifampicin, an anti-tuberculosis agent and potent inducer of drug metabolizing enzymes and transporters, with antiretroviral medication including HIV protease inhibitors is of high clinical relevance. As outlined in Table 4A, reductions in HIV protease inhibitor exposure when combined with rifampicin range from 75% to 89%, even in the presence of ritonavir as a boosting agent. When different LPV/r regimens combined with rifampicin were evaluated by la Porte et al., LPV/r combinations with higher ritonavir dose levels (i.e. LPV/r 400/400 > LPV/r 800/200) appeared to provide better compensation for the inducing effects of rifampicin.⁷⁶ This was especially reflected in the C_{min} concentrations achieved with the LPV/r 400/400 dose regimen, which tended to be comparable to the C_{min} concentrations achieved with the reference treatment of LPV/r 400/100 in the absence of rifampicin. Therefore, the use of rifabutin rather than rifampicin in the management of *M. Tuberculosis* infection in HIV positive patients on antiretroviral therapy is highly recommended.

IV. Transporter-mediated Processes Underlying Toxicity of HIV Protease Inhibitors

Both endogenous and exogenous (e.g. drugs) compounds are substrates for transporters. Interference of drugs with endogenous substrate transport may constitute a mechanism of drug-mediated toxicity. For example, interference of certain drugs (e.g. bosentan,

troglitazone) with hepatic bile salt transport has been implicated as one mechanism in the development of drug-induced cholestasis.⁷⁷ Several HIV protease inhibitors have been shown to interact with bile salt disposition in human and rat hepatocytes,⁷⁸ and this may explain, at least in part, the hepatotoxicity observed in some patients taking HIV protease inhibitors.⁷⁹ Rotger et al. quantified the effect of HIV protease inhibitor-containing antiretroviral therapy on the incidence of hyperbilirubinemia in 96 HIV-infected patients. Atazanavir and indinavir (but not lopinavir, saquinavir, ritonavir and nelfinavir) exhibited an increased incidence of elevated serum bilirubin concentrations.⁸⁰ Inhibition of the bilirubin conjugating enzyme UGT1A1 by these protease inhibitors has been proposed as a potential mechanism underlying this interaction. However, in vitro data generated by Campbell et al.⁸¹ and Ye et al.⁴⁷ also support potent inhibition of OATP1B3, the bilirubin-transporter, by indinavir and atazanavir. As noted in Table 6, the altered lipid metabolism associated with HIV protease inhibitor-based therapy may be caused by inhibition of transport of the endogenous substrate palmitate.⁸²

V. Influence of HIV Infection, Co-infection and Antiretroviral Therapy on Transporters: Implications for Protease Inhibitor Pharmacokinetics/ Pharmacodynamics

The effect of HIV infection on transporter expression and activity is not well understood. Effects of disease on P-gp mRNA expression and activity have been studied more extensively than other transport proteins. P-gp mRNA expression was decreased in leukocytes and PBMCs of SHIV infected macaques; changes in expression were more pronounced in animals receiving antiretroviral treatment that included indinavir. However, indinavir decreased P-gp expression, making it difficult to determine whether the disease state or indinavir itself were responsible for the observed effects;⁸³ similar findings have been reported in humans. Lucia and colleagues reported that P-gp function in peripheral blood lymphocytes, as measured by rhodamine-123 efflux, was decreased in HIV-infected patients. Separate clinical studies in patients with HIV infection relative to healthy volunteers support these findings, although expression of MRP1 in PBMCs was not altered.⁸⁴ Increased MRP-mediated efflux also has been reported in patients with primary HIV infection that strongly correlates with disease progression.⁸⁵ In contrast, a time-dependent significant *increase* in P-gp expression in PBMCs from HIV+ individuals has been reported.⁸⁶

The influence of hepatitis C co-infection on transporter function, and the potential implications for antiretroviral therapy, has been the subject of recent investigations due to the increasing prevalence of co-infection. MRP4 protein expression is induced in patients with cholestasis and animals with common bile duct ligation. These changes may facilitate compensatory MRP4-mediated basolateral efflux of endogenous compounds such as bile acids.⁸⁷⁻⁹⁰ MRP2 mRNA levels also are significantly decreased in human HCV-infected liver tissue relative to non-infected tissue.⁹¹ In addition, significant reductions in OCT1 and OATP1B1 mRNA which correlated with hepatitis C progression also have been reported in humans.⁹²

MRP1 expression in total human lymphocytes is unaffected by atazanavir treatment, but increased in human brain microvascular endothelial cells (HBMECs). P-gp expression, however, was increased in both total lymphocytes and HBMECs.⁹³ In human PBMCs, efavirenz-mediated induction of MRP1 and MRP6 mRNA has been reported. Tenofovir also was associated with a reduction in P-gp, MRP1, MRP5, and MRP6 mRNA expression in humans.⁹⁴

Regulation of transporter expression by nuclear receptors such as PXR and CAR is now well-established. For example, induction of P-gp and MRP1 by ritonavir, and P-gp by saquinavir, both PXR agonists, has been reported.⁹⁵⁻⁹⁷ Although a reduction in MRP1 protein expression in PBMCs of healthy volunteers following administration darunavir/ritonavir was observed, the clinically relevant consequences of these changes remain unclear.⁴⁸

Evidence in the literature demonstrating a direct effect of HIV infection, coinfection and HAART therapy on transporter phenotype and function remains limited and controversial for a number of reasons. The contribution of HIV infection, underlying symptoms, coinfection and antiretroviral therapy to pathophysiological changes are multifactorial and difficult to distinguish. In addition, appropriate models to investigate the intricate relationships are limited. The effect of HIV infection and co-infection on transporter function is the subject of ongoing investigations.

VI. Conclusion

HIV protease inhibitors that interact with transport proteins are likely candidates for DDIs resulting in toxicity or the development of cellular resistance. Consequently, chemotherapeutic agents exhibit limited minimal interactions with transport proteins such as P-gp are preferred.⁹⁸ Conversely, therapeutic agents that competitively inhibit transporters governing efflux may increase victim drug concentrations in relevant organs and tissues (e.g. lymphocytes), thereby enhancing efficacy and decreasing pill burden. For example, Pluronic P85, an amphiphilic block copolymer and P-gp inhibitor, increases saquinavir and nelfinavir accumulation in MDCKII-MDR1 cells.⁹⁹ Modulation of transport function is particularly promising given the difficulty of antiretrovirals to penetrate sites of viral sequestration, such as the brain, which expresses a number of efflux transporters known to interact with protease inhibitors, including P-gp, BCRP and MRPs.¹⁰⁰⁻¹⁰² In addition to transporter interactions, HIV protease inhibitors may interact with cytochrome P450s, modify posttranscriptional regulation of nuclear receptors, and alter bile acid biosynthesis and metabolism. Gender, genetic polymorphisms and lifestyle choices such as smoking and alcohol consumption also must be taken into consideration when trying to predict the likelihood of drug-transporter interactions. Toxicity and efficacy associated with these interactions is undoubtedly multifactorial and remains difficult to predict. However clinicians, scientists and regulatory agencies are becoming increasingly aware of the importance of understanding the dynamics of these relationships and are working together to ensure the emergence of safe and efficacious chemotherapeutic treatment options.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This research was supported by a grant from the National Institutes of Health (R01 GM41935; Bethesda, Maryland, USA).

References

1. Bragman K. Saquinavir: an HIV proteinase inhibitor. *Adv Exp Med Biol.* 1996; 394:305–317. [PubMed: 8815695]
2. Antiretroviral drugs used in the treatment of HIV infection. ed.: FDA website; 2011.
3. Thompson MA, Aberg JA, Cahn P, Montaner JS, Rizzardini G, Telenti A, Gatell JM, Gunthard HF, Hammer SM, Hirsch MS, Jacobsen DM, Reiss P, Richman DD, Volberding PA, Yeni P, Schooley

- RT. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. *JAMA*. 2010; 304(3):321–333. [PubMed: 20639566]
4. Bierman W, van Agtmael M, Nijhuis M, Danner S, Boucher C. HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review. *AIDS*. 2009; 23(3):279–291. [PubMed: 19114854]
 5. Thompson M, Aberg J, Cahn P, Montaner J, Rizzardini G, Telenti A, Gatell J, Gunthard H, Hammer S, Hirsch M, Jacobsen D, Reiss P, Richman D, Volberding P, Yeni P, Schooley R. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. *JAMA*. 2010; 304(3):321–333. [PubMed: 20639566]
 6. Busse K, Penzak S. Darunavir: a second-generation protease inhibitor. *Am J Health Syst Pharm*. 2007; 64(15):1593–1602. [PubMed: 17646561]
 7. Hull M, Montaner J. Ritonavir-boosted protease inhibitors in HIV therapy. *Ann Med*. 2011
 8. Josephson F. Drug-drug interactions in the treatment of HIV infection: focus on pharmacokinetic enhancement through CYP3A inhibition. *J Intern Med*. 2010; 268(6):530–539. [PubMed: 21073558]
 9. Moyle G, Back D. Principles and practice of HIV-protease inhibitor pharmacoenhancement. *HIV Med*. 2001; 2(2):105–113. [PubMed: 11737387]
 10. Youle M. Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients. *J Antimicrob Chemother*. 2007; 60(6):1195–1205. [PubMed: 17890281]
 11. McComsey G, Rightmire A, Wirtz V, Yang R, Mathew M, McGrath D. Changes in body composition with ritonavir-boosted and unboosted atazanavir treatment in combination with Lamivudine and Stavudine: a 96-week randomized, controlled study. *Clin Infect Dis*. 2009; 48(9):1323–1326. [PubMed: 19302017]
 12. Gallant JE. Protease-inhibitor boosting in the treatment-experienced patient. *AIDS Rev*. 2004; 6(4):226–233. [PubMed: 15700621]
 13. Chaudhary M, Gupta S, Khare S, Lal S. Diagnosis of tuberculosis in an era of HIV pandemic: a review of current status and future prospects. *Indian J Med Microbiol*. 2010; 28(4):281–289. [PubMed: 20966555]
 14. Parker AJ, Houston JB. Rate-limiting steps in hepatic drug clearance: comparison of hepatocellular uptake and metabolism with microsomal metabolism of saquinavir, nelfinavir, and ritonavir. *Drug Metab Dispos*. 2008; 36(7):1375–1384. [PubMed: 18426953]
 15. Kis O, Robillard K, Chan GN, Bendayan R. The complexities of antiretroviral drug-drug interactions: role of ABC and SLC transporters. *Trends Pharmacol Sci*. 2010; 31(1):22–35. [PubMed: 20004485]
 16. Tamai I, Nezu J, Uchino H, Sai Y, Oku A, Shimane M, Tsuji A. Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. *Biochem Biophys Res Commun*. 2000; 273(1):251–260. [PubMed: 10873595]
 17. Kim RB. Organic anion-transporting polypeptide (OATP) transporter family and drug disposition. *Eur J Clin Invest*. 2003; 33(2):1–5. [PubMed: 14641549]
 18. Su Y, Zhang X, Sinko PJ. Human organic anion-transporting polypeptide OATP-A (SLC21A3) acts in concert with P-glycoprotein and multidrug resistance protein 2 in the vectorial transport of Saquinavir in Hep G2 cells. *Mol Pharm*. 2004; 1(1):49–56. [PubMed: 15832500]
 19. Hartkoorn RC, Kwan WS, Shallcross V, Chaikan A, Liptrott N, Egan D, Sora ES, James CE, Gibbons S, Bray PG, Back DJ, Khoo SH, Owen A. HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms. *Pharmacogenet Genomics*. 2010; 20(2):112–120. [PubMed: 20051929]
 20. Janneh O, Hartkoorn R, Jones E, Owen A, Ward S, Davey R, Back D, Khoo S. Cultured CD4T cells and primary human lymphocytes express hOATPs: intracellular accumulation of saquinavir and lopinavir. *Br J Pharmacol*. 2008; 155(6):875–883. [PubMed: 19002102]
 21. Annaert P, Ye ZW, Stieger B, Augustijns P. Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1. *Xenobiotica*. 2010; 40(3):163–176. [PubMed: 20102298]
 22. Kis O, Zastre JA, Ramaswamy M, Bendayan R. pH dependence of organic anion-transporting polypeptide 2B1 in Caco-2 cells: potential role in antiretroviral drug oral bioavailability and drug-drug interactions. *J Pharmacol Exp Ther*. 2010; 334(3):1009–1022. [PubMed: 20507927]

23. Lubomirov R, di Iulio J, Fayet A, Colombo S, Martinez R, Marzolini C, Furrer H, Vernazza P, Calmy A, Cavassini M, Ledergerber B, Rentsch K, Descombes P, Buclin T, Decosterd LA, Csajka C, Telenti A. ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir. *Pharmacogenet Genomics*. 2010; 20(4):217–230. [PubMed: 20139798]
24. Zhang L, Brett CM, Giacomini KM. Role of organic cation transporters in drug absorption and elimination. *Annu Rev Pharmacol Toxicol*. 1998; 38:431–460. [PubMed: 9597162]
25. Jung N, Lehmann C, Rubbert A, Knispel M, Hartmann P, van Lunzen J, Stellbrink HJ, Faetkenheuer G, Taubert D. Relevance of the organic cation transporters 1 and 2 for antiretroviral drug therapy in human immunodeficiency virus infection. *Drug Metab Dispos*. 2008; 36(8):1616–1623. [PubMed: 18490433]
26. Zhang L, Gorset W, Washington CB, Blaschke TF, Kroetz DL, Giacomini KM. Interactions of HIV protease inhibitors with a human organic cation transporter in a mammalian expression system. *Drug Metab Dispos*. 2000; 28(3):329–334. [PubMed: 10681378]
27. Glavinas H, Krajcsi P, Cserepes J, Sarkadi B. The role of ABC transporters in drug resistance, metabolism and toxicity. *Curr Drug Deliv*. 2004; 1(1):27–42. [PubMed: 16305368]
28. Weiss J, Haefeli WE. Impact of ATP-binding cassette transporters on human immunodeficiency virus therapy. *Int Rev Cell Mol Biol*. 2010; 280:219–279. [PubMed: 20797684]
29. Schinkel AH, Jonker JW. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. *Adv Drug Deliv Rev*. 2003; 55(1):3–29. [PubMed: 12535572]
30. Park S, Sinko PJ. P-glycoprotein and multidrug resistance-associated proteins limit the brain uptake of saquinavir in mice. *J Pharmacol Exp Ther*. 2005; 312(3):1249–1256. [PubMed: 15528451]
31. Kim RB, Fromm MF, Wandel C, Leake B, Wood AJ, Roden DM, Wilkinson GR. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. *J Clin Invest*. 1998; 101(2):289–294. [PubMed: 9435299]
32. Agarwal S, Pal D, Mitra AK. Both P-gp and MRP2 mediate transport of Lopinavir, a protease inhibitor. *Int J Pharm*. 2007; 339(1-2):139–147. [PubMed: 17451894]
33. Kim R, Fromm M, Wandel C, Leake B, Wood A, Roden D, Wilkinson G. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. *J Clin Invest*. 1998; 101(2):289–294. [PubMed: 9435299]
34. Konig S, Herzog M, Theile D, Zembruski N, Haefeli W, Weiss J. Impact of drug transporters on cellular resistance towards saquinavir and darunavir. *J Antimicrob Chemother*. 2010; 65(11):2319–2328. [PubMed: 20817741]
35. van der Sandt IC, Vos CM, Nabulsi L, Blom-Roosemalen MC, Voorwinden HH, de Boer AG, Breimer DD. Assessment of active transport of HIV protease inhibitors in various cell lines and the in vitro blood–brain barrier. *Aids*. 2001; 15(4):483–491. [PubMed: 11242145]
36. van Waterschoot R, ter Heine R, Wagenaar E, van der Kruijssen C, Rooswinkel R, Huitema A, Beijnen J, Schinkel A. Effects of cytochrome P450 3A (CYP3A) and the drug transporters P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) on the pharmacokinetics of lopinavir. *Br J Pharmacol*. 2010; 160(5):1224–1233. [PubMed: 20590614]
37. Tong L, Phan TK, Robinson KL, Babusis D, Strab R, Bhoopathy S, Hidalgo IJ, Rhodes GR, Ray AS. Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro. *Antimicrob Agents Chemother*. 2007; 51(10):3498–3504. [PubMed: 17664327]
38. Konig SK, Herzog M, Theile D, Zembruski N, Haefeli WE, Weiss J. Impact of drug transporters on cellular resistance towards saquinavir and darunavir. *J Antimicrob Chemother*. 2010; 65(11):2319–2328. [PubMed: 20817741]
39. Bierman WF, Scheffer GL, Schoonderwoerd A, Jansen G, van Agtmael MA, Danner SA, Scheper RJ. Protease inhibitors atazanavir, lopinavir and ritonavir are potent blockers, but poor substrates, of ABC transporters in a broad panel of ABC transporter-overexpressing cell lines. *J Antimicrob Chemother*. 2010; 65(8):1672–1680. [PubMed: 20551216]

40. Gupta A, Zhang Y, Unadkat JD, Mao Q. HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2). *J Pharmacol Exp Ther.* 2004; 310(1): 334–341. [PubMed: 15007102]
41. Weiss J, Rose J, Storch CH, Ketabi-Kiyanvash N, Sauer A, Haefeli WE, Efferth T. Modulation of human BCRP (ABCG2) activity by anti-HIV drugs. *J Antimicrob Chemother.* 2007; 59(2):238–245. [PubMed: 17202245]
42. Ronaldson PT, Persidsky Y, Bendayan R. Regulation of ABC membrane transporters in glial cells: relevance to the pharmacotherapy of brain HIV-1 infection. *Glia.* 2008; 56(16):1711–1735. [PubMed: 18649402]
43. Leslie EM, Deeley RG, Cole SP. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. *Toxicol Appl Pharmacol.* 2005; 204(3):216–237. [PubMed: 15845415]
44. Jedlitschky G, Leier I, Buchholz U, Hummel-Eisenbeiss J, Burchell B, Keppler D. ATP-dependent transport of bilirubin glucuronides by the multidrug resistance protein MRP1 and its hepatocyte canalicular isoform MRP2. *Biochem J.* 1997; 327(Pt 1):305–310. [PubMed: 9355767]
45. Keppler D. Multidrug resistance proteins (MRPs, ABCs): importance for pathophysiology and drug therapy. *Handb Exp Pharmacol.* 2011; 201:299–323. [PubMed: 21103974]
46. Huisman MT, Smit JW, Crommentuyn KM, Zelcer N, Wiltshire HR, Beijnen JH, Schinkel AH. Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs. *Aids.* 2002; 16(17):2295–2301. [PubMed: 12441801]
47. Ye ZW, Camus S, Augustijns P, Annaert P. Interaction of eight HIV protease inhibitors with the canalicular efflux transporter ABCC2 (MRP2) in sandwich-cultured rat and human hepatocytes. *Biopharm Drug Dispos.* 2010; 31(2-3):178–188. [PubMed: 20238377]
48. Lee LS, Soon GH, Shen P, Yong EL, Flexner C, Pham P. Darunavir/ritonavir and efavirenz exert differential effects on MRP1 transporter expression and function in healthy volunteers. *Antivir Ther.* 2010; 15(2):275–279. [PubMed: 20386083]
49. Back DJ. Drug-drug interactions that matter. *Top HIV Med.* 2006; 14(2):88–92. [PubMed: 16835464]
50. Pal D, Mitra A. MDR- and CYP3A4-mediated drug-drug interactions. *J Neuroimmune Pharmacol.* 2006; 1(3):323–339. [PubMed: 18040809]
51. Dam E, Lebel-Binay S, Rochas S, Thibaut L, Faudon J, Thomas C, Essioux L, Hill A, Schutz M, Clavel F. Synergistic inhibition of protease-inhibitor-resistant HIV type 1 by saquinavir in combination with atazanavir or lopinavir. *Antivir Ther.* 2007; 12(3):371–380. [PubMed: 17591027]
52. Scholler-Gyure M, Kakuda T, Sekar V, Woodfall B, De Smedt G, Lefebvre E, Peeters M, Hoetelmans R. Pharmacokinetics of darunavir/ritonavir and TMC125 alone and coadministered in HIV-negative volunteers. *Antivir Ther.* 2007; 12(5):789–796. [PubMed: 17713162]
53. Ford J, Boffito M, Maitland D, Hill A, Back D, Khoo S, Nelson M, Moyle G, Gazzard B, Pozniak A. Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients. *J Antimicrob Chemother.* 2006; 58(5):1009–1016. [PubMed: 16984898]
54. Kharasch E, Hoffer C, Whittington D, Walker A, Bedynek P. Methadone pharmacokinetics are independent of cytochrome P4503A (CYP3A) activity and gastrointestinal drug transport: insights from methadone interactions with ritonavir/indinavir. *Anesthesiology.* 2009; 110(3):660–672. [PubMed: 19225389]
55. Wyen C, Fuhr U, Frank D, Aarnoutse R, Klaassen T, Lazar A, Seeringer A, Doroshenko O, Kirchheiner J, Abdulrazik F, Schmeisser N, Lehmann C, Hein W, Schomig E, Burger D, Fatkenheuer G, Jetter A. Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patients. *Clin Pharmacol Ther.* 2008; 84(1):75–82. [PubMed: 18183034]
56. Tayrouz Y, Ganssmann B, Ding R, Klingmann A, Aderjan R, Burhenne J, Haefeli W, Mikus G. Ritonavir increases loperamide plasma concentrations without evidence for P-glycoprotein involvement. *Clin Pharmacol Ther.* 2001; 70(5):405–414. [PubMed: 11719726]

57. Barau C, Blouin P, Creput C, Taburet A, Durrbach A, Furlan V. Effect of coadministered HIV-protease inhibitors on tacrolimus and sirolimus blood concentrations in a kidney transplant recipient. *Fundam Clin Pharmacol*. 2009; 23(4):423–425. [PubMed: 19709321]
58. Mertz D, Battegay M, Marzolini C, Mayr M. Drug-drug interaction in a kidney transplant recipient receiving HIV salvage therapy and tacrolimus. *Am J Kidney Dis*. 2009; 54(1):e1–4. [PubMed: 19346040]
59. Tong L, Phan T, Robinson K, Babusis D, Strab R, Bhoopathy S, Hidalgo I, Rhodes G, Ray A. Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro. *Antimicrob Agents Chemother*. 2007; 51(10):3498–3504. [PubMed: 17664327]
60. van Gelder J, Deferme S, Naesens L, De Clercq E, van den Mooter G, Kinget R, Augustijns P. Intestinal absorption enhancement of the ester prodrug tenofovir disoproxil fumarate through modulation of the biochemical barrier by defined ester mixtures. *Drug Metab Dispos*. 2002; 30(8):924–930. [PubMed: 12124311]
61. Shitara Y. Clinical importance of OATP1B1 and OATP1B3 in drug-drug interactions. *Drug Metab Pharmacokinet*. 2011
62. Pham P, la Porte C, Lee L, van Heeswijk R, Sabo J, Elgadi M, Piliero P, Barditch-Crovo P, Fuchs E, Flexner C, Cameron D. Differential effects of tipranavir plus ritonavir on atorvastatin or rosuvastatin pharmacokinetics in healthy volunteers. *Antimicrob Agents Chemother*. 2009; 53(10):4385–4392. [PubMed: 19667285]
63. Colucci P, Pottage J, Robison H, Turgeon J, Ducharme M. Effect of a single dose of ritonavir on the pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered in healthy volunteers. *Antimicrob Agents Chemother*. 2009; 53(2):646–650. [PubMed: 19015353]
64. Holmstock N, Mols R, Annaert P, Augustijns P. In situ intestinal perfusion in knockout mice demonstrates inhibition of intestinal p-glycoprotein by ritonavir causing increased darunavir absorption. *Drug Metab Dispos*. 2010; 38(9):1407–1410. [PubMed: 20551242]
65. di Masi A, De Marinis E, Ascenzi P, Marino M. Nuclear receptors CAR and PXR: Molecular, functional, and biomedical aspects. *Mol Aspects Med*. 2009; 30(5):297–343. [PubMed: 19427329]
66. Meyer zu Schwabedissen H, Kim R. Hepatic OATP1B transporters and nuclear receptors PXR and CAR: interplay, regulation of drug disposition genes, and single nucleotide polymorphisms. *Mol Pharm*. 2009; 6(6):1644–1661. [PubMed: 19558188]
67. Dixit V, Hariparsad N, Li F, Desai P, Thummel K, Unadkat J. Cytochrome P450 enzymes and transporters induced by anti-human immunodeficiency virus protease inhibitors in human hepatocytes: implications for predicting clinical drug interactions. *Drug Metab Dispos*. 2007; 35(10):1853–1859. [PubMed: 17639026]
68. Foisy M, Yakiwchuk E, Hughes C. Induction effects of ritonavir: implications for drug interactions. *Ann Pharmacother*. 2008; 42(7):1048–1059. [PubMed: 18577765]
69. Mukwaya G, MacGregor T, Hoelscher D, Heming T, Legg D, Kavanaugh K, Johnson P, Sabo J, McCallister S. Interaction of ritonavir-boosted tipranavir with loperamide does not result in loperamide-associated neurologic side effects in healthy volunteers. *Antimicrob Agents Chemother*. 2005; 49(12):4903–4910. [PubMed: 16304151]
70. Dumond J, Vourvahis M, Rezk N, Patterson K, Tien H, White N, Jennings S, Choi S, Li J, Wagner M, La-Beck N, Drulak M, Sabo J, Castles M, Macgregor T, Kashuba A. A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir. *Clin Pharmacol Ther*. 2010; 87(6):735–742. [PubMed: 20147896]
71. Kharasch E, Walker A, Whittington D, Hoffer C, Bedynek P. Methadone metabolism and clearance are induced by nelfinavir despite inhibition of cytochrome P4503A (CYP3A) activity. *Drug Alcohol Depend*. 2009; 101(3):158–168. [PubMed: 19232844]
72. Justesen U, Klitgaard N, Brosen K, Pedersen C. Pharmacokinetic interaction between amprenavir and delavirdine after multiple-dose administration in healthy volunteers. *Br J Clin Pharmacol*. 2003; 55(1):100–106. [PubMed: 12534646]

73. Kakuda T, Scholler-Gyure M, Hoetelmans R. Clinical perspective on antiretroviral drug-drug interactions with the non-nucleoside reverse transcriptase inhibitor etravirine. *Antivir Ther.* 2010; 15(6):817–829. [PubMed: 20834094]
74. Scholler-Gyure M, Kakuda T, Raoof A, De Smedt G, Hoetelmans R. Clinical pharmacokinetics and pharmacodynamics of etravirine. *Clin Pharmacokinet.* 2009; 48(9):561–574. [PubMed: 19725591]
75. Zembruski N, Haefeli W, Weiss J. Interaction potential of etravirine with drug transporters assessed in vitro. *Antimicrob Agents Chemother.* 2010
76. la Porte C, Colbers E, Bertz R, Voncken D, Wikstrom K, Boeree M, Koopmans P, Hekster Y, Burger D. Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers. *Antimicrob Agents Chemother.* 2004; 48(5):1553–1560. [PubMed: 15105105]
77. Fattinger K, Funk C, Pantze M, Weber C, Reichen J, Stieger B, Meier P. The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. *Clin Pharmacol Ther.* 2001; 69(4):223–231. [PubMed: 11309550]
78. McRae M, Lowe C, Tian X, Bourdet D, Ho R, Leake B, Kim R, Brouwer K, Kashuba A. Ritonavir, saquinavir, and efavirenz, but not nevirapine, inhibit bile acid transport in human and rat hepatocytes. *J Pharmacol Exp Ther.* 2006; 318(3):1068–1075. [PubMed: 16720753]
79. McRae M, Rezk N, Bridges A, Corbett A, Tien H, Brouwer K, Kashuba A. Plasma bile acid concentrations in patients with human immunodeficiency virus infection receiving protease inhibitor therapy: possible implications for hepatotoxicity. *Pharmacotherapy.* 2010; 30(1):17–24. [PubMed: 20030469]
80. Rotger M, Taffe P, Bleiber G, Gunthard H, Furrer H, Vernazza P, Drechsler H, Bernasconi E, Rickenbach M, Telenti A. Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia. *J Infect Dis.* 2005; 192(8):1381–1386. [PubMed: 16170753]
81. Campbell SD, de Morais SM, Xu JJ. Inhibition of human organic anion transporting polypeptide OATP 1B1 as a mechanism of drug-induced hyperbilirubinemia. *Chem Biol Interact.* 2004; 150(2):179–187. [PubMed: 15535988]
82. Richmond S, Carper M, Lei X, Zhang S, Yarasheski K, Ramanadham S. HIV-protease inhibitors suppress skeletal muscle fatty acid oxidation by reducing CD36 and CPT1 fatty acid transporters. *Biochim Biophys Acta.* 2010; 1801(5):559–566. [PubMed: 20117238]
83. Jorajuria S, Clayette P, Dereuddre-Bosquet N, Benlhassan-Chahour K, Thiebot H, Vaslin B, Le Grand R, Dormont D. The expression of P-glycoprotein and cellular kinases is modulated at the transcriptional level by infection and highly active antiretroviral therapy in a primate model of AIDS. *AIDS Res Hum Retroviruses.* 2003; 19(4):307–311. [PubMed: 12804006]
84. Meaden ER, Hoggard PG, Maher B, Khoo SH, Back DJ. Expression of P-glycoprotein and multidrug resistance-associated protein in healthy volunteers and HIV-infected patients. *AIDS Res Hum Retroviruses.* 2001; 17(14):1329–1332. [PubMed: 11602043]
85. Lucia MB, Savarino A, Straface E, Golotta C, Rastrelli E, Matarrese P, Rutella S, Malorni W, Cauda R. Role of lymphocyte multidrug resistance protein 1 in HIV infection: expression, function, and consequences of inhibition. *J Acquir Immune Defic Syndr.* 2005; 40(3):257–266. [PubMed: 16249698]
86. Andreana A, Aggarwal S, Gollapudi S, Wien D, Tsuruo T, Gupta S. Abnormal expression of a 170-kilodalton P-glycoprotein encoded by MDR1 gene, a metabolically active efflux pump, in CD4+ and CD8+ T cells from patients with human immunodeficiency virus type 1 infection. *AIDS Res Hum Retroviruses.* 1996; 12(15):1457–1462. [PubMed: 8893053]
87. Denk GU, Soroka CJ, Takeyama Y, Chen WS, Schuetz JD, Boyer JL. Multidrug resistance-associated protein 4 is up-regulated in liver but down-regulated in kidney in obstructive cholestasis in the rat. *J Hepatol.* 2004; 40(4):585–591. [PubMed: 15030973]
88. Gradhand U, Lang T, Schaeffeler E, Glaeser H, Tegude H, Klein K, Fritz P, Jedlitschky G, Kroemer HK, Bachmakov I, Anwald B, Kerb R, Zanger UM, Eichelbaum M, Schwab M, Fromm MF. Variability in human hepatic MRP4 expression: influence of cholestasis and genotype. *Pharmacogenomics J.* 2008; 8(1):42–52. [PubMed: 17404579]

89. Ogasawara K, Terada T, Katsura T, Hatano E, Ikai I, Yamaoka Y, Inui K. Hepatitis C virus-related cirrhosis is a major determinant of the expression levels of hepatic drug transporters. *Drug Metab Pharmacokinet.* 2010; 25(2):190–199. [PubMed: 20460825]
90. Wagner M, Fickert P, Zollner G, Fuchsbichler A, Silbert D, Tsybrovskyy O, Zatloukal K, Guo GL, Schuetz JD, Gonzalez FJ, Marschall HU, Denk H, Trauner M. Role of farnesoid X receptor in determining hepatic ABC transporter expression and liver injury in bile duct-ligated mice. *Gastroenterology.* 2003; 125(3):825–838. [PubMed: 12949728]
91. Hinoshita E, Taguchi K, Inokuchi A, Uchiumi T, Kinukawa N, Shimada M, Tsuneyoshi M, Sugimachi K, Kuwano M. Decreased expression of an ATP-binding cassette transporter, MRP2, in human livers with hepatitis C virus infection. *J Hepatol.* 2001; 35(6):765–773. [PubMed: 11738104]
92. Nakai K, Tanaka H, Hanada K, Ogata H, Suzuki F, Kumada H, Miyajima A, Ishida S, Sunouchi M, Habano W, Kamikawa Y, Kubota K, Kita J, Ozawa S, Ohno Y. Decreased expression of cytochromes P450 1A2, 2E1, and 3A4 and drug transporters Na⁺-taurocholate-cotransporting polypeptide, organic cation transporter 1, and organic anion-transporting peptide-C correlates with the progression of liver fibrosis in chronic hepatitis C patients. *Drug Metab Dispos.* 2008; 36(9):1786–1793. [PubMed: 18515332]
93. Bousquet L, Roucairol C, Hembury A, Nevers MC, Creminon C, Farinotti R, Mabondzo A. Comparison of ABC transporter modulation by atazanavir in lymphocytes and human brain endothelial cells: ABC transporters are involved in the atazanavir-limited passage across an in vitro human model of the blood-brain barrier. *AIDS Res Hum Retroviruses.* 2008; 24(9):1147–1154. [PubMed: 18729774]
94. Bousquet L, Pruvost A, Guyot AC, Farinotti R, Mabondzo A. Combination of tenofovir and emtricitabine plus efavirenz: in vitro modulation of ABC transporter and intracellular drug accumulation. *Antimicrob Agents Chemother.* 2009; 53(3):896–902. [PubMed: 19075072]
95. Dussault I, Lin M, Hollister K, Wang EH, Synold TW, Forman BM. Peptide mimetic HIV protease inhibitors are ligands for the orphan receptor SXR. *J Biol Chem.* 2001; 276(36):33309–33312. [PubMed: 11466304]
96. Gupta A, Mugundu G, Desai P, Thummel K, Unadkat J. Intestinal human colon adenocarcinoma cell line LS180 is an excellent model to study pregnane X receptor, but not constitutive androstane receptor, mediated CYP3A4 and multidrug resistance transporter 1 induction: studies with anti-human immunodeficiency virus protease inhibitors. *Drug Metab Dispos.* 2008; 36(6):1172–1180. [PubMed: 18332086]
97. Perloff M, Von Moltke L, Marchand J, Greenblatt D. Ritonavir induces P-glycoprotein expression, multidrug resistance-associated protein (MRP1) expression, and drug transporter-mediated activity in a human intestinal cell line. *J Pharm Sci.* 2001; 90(11):1829–1837. [PubMed: 11745741]
98. Coburger C, Lage H, Molnar J, Langner A, Hilgeroth A. Multidrug resistance reversal properties and cytotoxic evaluation of representatives of a novel class of HIV-1 protease inhibitors. *J Pharm Pharmacol.* 2010; 62(12):1704–1710. [PubMed: 21054396]
99. Shaik N, Pan G, Elmquist WF. Interactions of pluronic block copolymers on P-gp efflux activity: experience with HIV-1 protease inhibitors. *J Pharm Sci.* 2008; 97(12):5421–5433. [PubMed: 18393290]
100. Golden PL, Pollack GM. Blood-brain barrier efflux transport. *J Pharm Sci.* 2003; 92(9):1739–1753. [PubMed: 12949994]
101. Thomas SA. Anti-HIV drug distribution to the central nervous system. *Curr Pharm Des.* 2004; 10(12):1313–1324. [PubMed: 15134483]
102. Choo EF, Leake B, Wandel C, Imamura H, Wood AJ, Wilkinson GR, Kim RB. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. *Drug Metab Dispos.* 2000; 28(6):655–660. [PubMed: 10820137]
103. Ford J, Khoo SH, Back DJ. The intracellular pharmacology of antiretroviral protease inhibitors. *J Antimicrob Chemother.* 2004; 54(6):982–990. [PubMed: 15537695]
104. Kashuba A, Dyer J, Kramer L, Raasch R, Eron J, Cohen M. Antiretroviral-drug concentrations in semen: implications for sexual transmission of human immunodeficiency virus type 1. *Antimicrob Agents Chemother.* 1999; 43(8):1817–1826. [PubMed: 10428898]

105. Williams GC, Sinko PJ. Oral absorption of the HIV protease inhibitors: a current update. *Adv Drug Deliv Rev.* 1999; 39(1-3):211–238. [PubMed: 10837775]
106. Loregian A, Pagni S, Ballarin E, Sinigalia E, Parisi S, Palu G. Simple determination of the HIV protease inhibitor atazanavir in human plasma by high-performance liquid chromatography with UV detection. *J Pharm Biomed Anal.* 2006; 42(4):500–505. [PubMed: 16765009]
107. Lin J. Human immunodeficiency virus protease inhibitors. From drug design to clinical studies. *Adv Drug Deliv Rev.* 1997; 27(2-3):215–233. [PubMed: 10837559]
108. Lin J, Chen I, Vastag K, Ostovic D. pH-dependent oral absorption of L-735,524, a potent HIV protease inhibitor, in rats and dogs. *Drug Metab Dispos.* 1995; 23(7):730–735. [PubMed: 7587962]
109. Bazzoli C, Jullien V, Le Tiec C, Rey E, Mentre F, Taburet A. Intracellular Pharmacokinetics of Antiretroviral Drugs in HIV-Infected Patients, and their Correlation with Drug Action. *Clin Pharmacokinet.* 2010; 49(1):17–45. [PubMed: 20000887]
110. Longer M, Shetty B, Zamansky I, Tyle P. Preformulation studies of a novel HIV protease inhibitor, AG1343. *J Pharm Sci.* 1995; 84(9):1090–1093. [PubMed: 8537887]
111. McEvoy, GK., editor. *AHFS Drug Information 2010*. Bethesda, Maryland: American Society of Health-Systems Pharmacists; 2010.
112. Vertex Ga Lexiva (fosamprenavir) US prescribing information. [last accessed: 2 March 2011] Available at <http://www.lexiva.com/>
113. Havlir D, O'Marro S. Atazanavir: new option for treatment of HIV infection. *Clin Infect Dis.* 2004; 38(11):1599–1604. [PubMed: 15156449]
114. Dickinson L, Khoo S, Back D. Pharmacokinetics and drug-drug interactions of antiretrovirals: an update. *Antiviral Res.* 2010; 85(1):176–189. [PubMed: 19665485]
115. Rittweger M, Arasteh K. Clinical pharmacokinetics of darunavir. *Clin Pharmacokinet.* 2007; 46(9):739–756. [PubMed: 17713972]
116. Merck Crixivan (indinavir) US Prescribing Information. [last accessed: 2 March 2011] Available at <http://www.crixivan.com/>
117. Laboratories A Kaletra (lopinavir/ritonavir) US Prescribing Information. [last accessed: 2 March 2011] Available at <http://www.kaletra.com/>
118. Le Tiec C, Barrail A, Goujard C, Taburet A. Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir. *Clin Pharmacokinet.* 2005; 44(10):1035–1050. [PubMed: 16176117]
119. Bachmeier CJ, Spitzenberger TJ, Elmquist WF, Miller DW. Quantitative assessment of HIV-1 protease inhibitor interactions with drug efflux transporters in the blood-brain barrier. *Pharm Res.* 2005; 22(8):1259–1268. [PubMed: 16078135]
120. Brown KC, Paul S, Kashuba AD. Drug interactions with new and investigational antiretrovirals. *Clin Pharmacokinet.* 2009; 48(4):211–241. [PubMed: 19492868]
121. Tirona RG, Leake BF, Wolkoff AW, Kim RB. Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. *J Pharmacol Exp Ther.* 2003; 304(1):223–228. [PubMed: 12490595]
122. Cook JA, Feng B, Fenner KS, Kempshall S, Liu R, Rotter C, Smith DA, Troutman MD, Ullah M, Lee CA. Refining the in vitro and in vivo critical parameters for P-glycoprotein, [I]/IC50 and [I2]/IC50, that allow for the exclusion of drug candidates from clinical digoxin interaction studies. *Mol Pharm.* 2010; 7(2):398–411. [PubMed: 20025245]
123. Perloff MD, von Moltke LL, Stormer E, Shader RI, Greenblatt DJ. Saint John's wort: an in vitro analysis of P-glycoprotein induction due to extended exposure. *Br J Pharmacol.* 2001; 134(8):1601–1608. [PubMed: 11739235]
124. Keogh JP, Kunta JR. Development, validation and utility of an in vitro technique for assessment of potential clinical drug-drug interactions involving P-glycoprotein. *Eur J Pharm Sci.* 2006; 27(5):543–554. [PubMed: 16406207]
125. Hirano M, Maeda K, Shitara Y, Sugiyama Y. Drug-drug interaction between pitavastatin and various drugs via OATP1B1. *Drug Metab Dispos.* 2006; 34(7):1229–1236. [PubMed: 16595711]

126. Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, Kim RB. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. *Drug Metab Dispos*. 1999; 27(8):866–871. [PubMed: 10421612]
127. Meyer zu Schwabedissen HE, Verstuyft C, Kroemer HK, Becquemont L, Kim RB. Human multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter: functional characterization, interaction with OCT2 (SLC22A2), and single nucleotide polymorphisms. *Am J Physiol Renal Physiol*. 2010; 298(4):F997–F1005. [PubMed: 20053795]
128. Haslam IS, Jones K, Coleman T, Simmons NL. Induction of P-glycoprotein expression and function in human intestinal epithelial cells (T84). *Biochem Pharmacol*. 2008; 76(7):850–861. [PubMed: 18703021]
129. Lee CG, Gottesman MM, Cardarelli CO, Ramachandra M, Jeang KT, Ambudkar SV, Pastan I, Dey S. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. *Biochemistry*. 1998; 37(11):3594–3601. [PubMed: 9530286]
130. Woodahl EL, Yang Z, Bui T, Shen DD, Ho RJ. MDR1 G1199A polymorphism alters permeability of HIV protease inhibitors across P-glycoprotein-expressing epithelial cells. *Aids*. 2005; 19(15):1617–1625. [PubMed: 16184031]
131. Collett A, Tanianis-Hughes J, Hallifax D, Warhurst G. Predicting P-glycoprotein effects on oral absorption: correlation of transport in Caco-2 with drug pharmacokinetics in wild-type and *mdr1a*(-/-) mice in vivo. *Pharm Res*. 2004; 21(5):819–826. [PubMed: 15180340]
132. McIlleron H, Meintjes G, Burman W, Maartens G. Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome. *J Infect Dis*. 2007; 196(1):S63–75. [PubMed: 17624828]
133. Brouwers J, Tack J, Lammert F, Augustijns P. Intraluminal drug and formulation behavior and integration in in vitro permeability estimation: a case study with amprenavir. *J Pharm Sci*. 2006; 95(2):372–383. [PubMed: 16374852]
134. Mouly SJ, Paine MF, Watkins PB. Contributions of CYP3A4, P-glycoprotein, and serum protein binding to the intestinal first-pass extraction of saquinavir. *J Pharmacol Exp Ther*. 2004; 308(3):941–948. [PubMed: 14718607]
135. Mallolas J, Sarasa M, Nomdedeu M, Soriano A, Lopez-Pua Y, Blanco J, Martinez E, Gatell J. Pharmacokinetic interaction between rifampicin and ritonavir-boosted atazanavir in HIV-infected patients. *HIV Med*. 2007; 8(2):131–134. [PubMed: 17352770]
136. Baciewicz A, Chrisman C, Finch C, Self T. Update on rifampin and rifabutin drug interactions. *Am J Med Sci*. 2008; 335(2):126–136. [PubMed: 18277121]
137. Yang X, Hu Z, Duan W, Zhu Y, Zhou S. Drug-herb interactions: eliminating toxicity with hard drug design. *Curr Pharm Des*. 2006; 12(35):4649–4664. [PubMed: 17168768]
138. Sekar V, Lefebvre E, De Pauw M, Vangeneugden T, Hoetelmans R. Pharmacokinetics of darunavir/ritonavir and ketoconazole following co-administration in HIV-healthy volunteers. *Br J Clin Pharmacol*. 2008; 66(2):215–221. [PubMed: 18460033]
139. Fujimoto H, Higuchi M, Watanabe H, Koh Y, Ghosh AK, Mitsuya H, Tanoue N, Hamada A, Saito H. P-glycoprotein mediates efflux transport of darunavir in human intestinal Caco-2 and ABCB1 gene-transfected renal LLC-PK1 cell lines. *Biol Pharm Bull*. 2009; 32(9):1588–1593. [PubMed: 19721237]
140. Khaliq Y, Gallicano K, Venance S, Kravcik S, Cameron D. Effect of ketoconazole on ritonavir and saquinavir concentrations in plasma and cerebrospinal fluid from patients infected with human immunodeficiency virus. *Clin Pharmacol Ther*. 2000; 68(6):637–646. [PubMed: 11180024]
141. Profit L, Eagling V, Back D. Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors. *AIDS*. 1999; 13(13):1623–1627. [PubMed: 10509562]
142. Sekar V, Lavreys L, Van de Castele T, Berckmans C, Spinosa-Guzman S, Vangeneugden T, De Pauw M, Hoetelmans R. Pharmacokinetics of darunavir/ritonavir and rifabutin coadministered in HIV-negative healthy volunteers. *Antimicrob Agents Chemother*. 2010; 54(10):4440–4445. [PubMed: 20660678]

143. Kiser J, Carten M, Aquilante C, Anderson P, Wolfe P, King T, Delahunty T, Bushman L, Fletcher C. The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients. *Clin Pharmacol Ther.* 2008; 83(2):265–272. [PubMed: 17597712]
144. Cihlar T, Ray A, Laflamme G, Vela J, Tong L, Fuller M, Roy A, Rhodes G. Molecular assessment of the potential for renal drug interactions between tenofovir and HIV protease inhibitors. *Antivir Ther.* 2007; 12(2):267–272. [PubMed: 17503669]
145. van Heeswijk R, Bourbeau M, Campbell P, Seguin I, Chauhan B, Foster B, Cameron D. Time-dependent interaction between lopinavir/ritonavir and fexofenadine. *J Clin Pharmacol.* 2006; 46(7):758–767. [PubMed: 16809801]
146. Perloff M, von Moltke L, Greenblatt D. Fexofenadine transport in Caco-2 cells: inhibition with verapamil and ritonavir. *J Clin Pharmacol.* 2002; 42(11):1269–1274. [PubMed: 12412827]
147. Fukushima K, Haraya K, Terasaka S, Ito Y, Sugioka N, Takada K. Long-term pharmacokinetic efficacy and safety of low-dose ritonavir as a booster and atazanavir pharmaceutical formulation based on solid dispersion system in rats. *Biol Pharm Bull.* 2008; 31(6):1209–1214. [PubMed: 18520056]
148. Kharasch E, Bedynek P, Walker A, Whittington D, Hoffer C. Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: II. Ritonavir effects on CYP3A and P-glycoprotein activities. *Clin Pharmacol Ther.* 2008; 84(4):506–512. [PubMed: 19238656]
149. Penzak S, Shen J, Alfaro R, Remaley A, Natarajan V, Falloon J. Ritonavir decreases the nonrenal clearance of digoxin in healthy volunteers with known MDR1 genotypes. *Ther Drug Monit.* 2004; 26(3):322–330. [PubMed: 15167636]
150. Bendayan R, Lee G, Bendayan M. Functional expression and localization of P-glycoprotein at the blood brain barrier. *Microsc Res Tech.* 2002; 57(5):365–380. [PubMed: 12112443]
151. Ding R, Tayrouz Y, Riedel KD, Burhenne J, Weiss J, Mikus G, Haefeli WE. Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers. *Clin Pharmacol Ther.* 2004; 76(1):73–84. [PubMed: 15229466]
152. Schmitt C, Kaeser B, Riek M, Bech N, Kreuzer C. Effect of saquinavir/ritonavir on P-glycoprotein activity in healthy volunteers using digoxin as a probe. *Int J Clin Pharmacol Ther.* 2010; 48(3):192–199. [PubMed: 20197013]
153. Sekar V, Lefebvre E, De Marez T, De Pauw M, De Paepe E, Vangeneugden T, Hoetelmans R. Effect of repeated doses of darunavir plus low-dose ritonavir on the pharmacokinetics of sildenafil in healthy male subjects: phase I randomized, open-label, two-way crossover study. *Clin Drug Investig.* 2008; 28(8):479–485.
154. Laboratories A Norvir (ritonavir) US Prescribing Information. [last accessed: 2 March 2011] Available at <http://www.norvir.com/>
155. Fichtenbaum C, Gerber J, Rosenkranz S, Segal Y, Aberg J, Blaschke T, Alston B, Fang F, Kosel B, Aweeka F. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. *AIDS.* 2002; 16(4):569–577. [PubMed: 11873000]
156. Hoetelmans, RMW.; Lasure, A.; Koester, A.; de Pauw, M.; van Baelen, B.; Peeters, M.; Parys, W.; Lefebvre, E. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; Washington, DC. 2004.
157. Huang L, Wang Y, Grimm S. ATP-dependent transport of rosuvastatin in membrane vesicles expressing breast cancer resistance protein. *Drug Metab Dispos.* 2006; 34(5):738–742. [PubMed: 16415124]
158. Hagenbuch B, Meier P. The superfamily of organic anion transporting polypeptides. *Biochim Biophys Acta.* 2003; 1609(1):1–18. [PubMed: 12507753]
159. Annaert P, Ye Z, Stieger B, Augustijns P. Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1. *Xenobiotica.* 2010; 40(3):163–176. [PubMed: 20102298]
160. Matsson P, Englund G, Ahlin G, Bergstrom C, Norinder U, Artursson P. A global drug inhibition pattern for the human ATP-binding cassette transporter breast cancer resistance protein (ABCG2). *J Pharmacol Exp Ther.* 2007; 323(1):19–30. [PubMed: 17616561]

161. Busti A, Bain A, Hall Rn, Bedimo R, Leff R, Meek C, Mehvar R. Effects of atazanavir/ritonavir or fosamprenavir/ritonavir on the pharmacokinetics of rosuvastatin. *J Cardiovasc Pharmacol*. 2008; 51(6):605–610. [PubMed: 18520949]
162. Watanabe T, Kusuhara H, Sugiyama Y. Application of physiologically based pharmacokinetic modeling and clearance concept to drugs showing transporter-mediated distribution and clearance in humans. *J Pharmacokinet Pharmacodyn*. 2010; 37(6):575–590. [PubMed: 21063755]
163. Toy J, Giguere P, Kravcik S, la Porte C. Drug interactions between voriconazole, darunavir/ritonavir and etravirine in an HIV-infected patient with *Aspergillus pneumonia*. *AIDS*. 2011; 25(4):541–542. [PubMed: 21293201]
164. Janneh O, Bray P, Jones E, Wyen C, Chiba P, Back D, Khoo S. Concentration-dependent effects and intracellular accumulation of HIV protease inhibitors in cultured CD4 T cells and primary human lymphocytes. *J Antimicrob Chemother*. 2010; 65(5):906–916. [PubMed: 20237075]
165. Haslam IS, Jones K, Coleman T, Simmons NL. Rifampin and digoxin induction of MDR1 expression and function in human intestinal (T84) epithelial cells. *Br J Pharmacol*. 2008; 154(1): 246–255. [PubMed: 18332862]
166. Perloff E, Duan S, Skolnik P, Greenblatt D, von Moltke L. Atazanavir: effects on P-glycoprotein transport and CYP3A metabolism in vitro. *Drug Metab Dispos*. 2005; 33(6):764–770. [PubMed: 15764714]
167. Zastre J, Chan G, Ronaldson P, Ramaswamy M, Couraud P, Romero I, Weksler B, Bendayan M, Bendayan R. Up-regulation of P-glycoprotein by HIV protease inhibitors in a human brain microvessel endothelial cell line. *J Neurosci Res*. 2009; 87(4):1023–1036. [PubMed: 18855943]
168. Vishnuvardhan D, Moltke LL, Richert C, Greenblatt DJ. Lopinavir: acute exposure inhibits P-glycoprotein; extended exposure induces P-glycoprotein. *Aids*. 2003; 17(7):1092–1094. [PubMed: 12700464]
169. Beghin D, Forestier F, Noel-Hudson M, Gavard L, Guibourdenche J, Farinotti R, Gil S. Modulation of endocrine and transport functions in human trophoblasts by saquinavir and nelfinavir. *Eur J Obstet Gynecol Reprod Biol*. 2010; 152(1):55–59. [PubMed: 20591557]
170. Perloff M, Stormer E, von Moltke L, Greenblatt D. Rapid assessment of P-glycoprotein inhibition and induction in vitro. *Pharm Res*. 2003; 20(8):1177–1183. [PubMed: 12948015]

Figure 1.

Schematic depicting the localization of SLC and ABC transport proteins involved in the translocation of protease inhibitors at sites of absorption (intestine), excretion (liver, kidney) and at target sites (central nervous system, lymphatic system, placenta, blood-testis barrier, and female genital tract). Protease inhibitors (PI) are transported (denoted by solid lines) into cells by proteins of the SLC family (e.g., OATPs and OCTs) and transported out of cells by proteins of the ABC family (e.g., P-gp, BCRP, MRPs). The hepatic uptake and excretion of bile acids (BA), which is mediated by NTCP and BSEP, respectively, is inhibited (denoted by dashed lines) by protease inhibitors. The hepatic transport of bilirubin, which is mediated by OATP1B1, is inhibited (denoted by dashed line) by protease inhibitors. Protease inhibitors bind to pregnane X receptor (PXR), an orphan nuclear receptor, which forms a heterodimer with the retinoid X-receptor- α (RXR) and mediate the induction of Cytochrome P450 3A4 (CYP3A4).

Table 1
Physicochemical properties and *in vitro* cellular accumulation ratios of HIV Protease Inhibitors

	Amprenavir (APV) [Fosamprenavir]	Atazanavir (ATZ)	Darunavir (DRV)	Indinavir (IDV)	Lopinavir (LPV)	Nelfinavir (NLV)	Ritonavir (RTV)	Saquinavir (SQV)	Tipranavir (TPV)
pKa	1.9 [#] [6.28] ^c	4.3	14.2	6.2; 5.9, 3.7;	1.6	6.0, 11.1	2.8	1.1, 7.1; 7.0; 5.5 ^b	7.8
Lipophilicity (Log P _{ow}) Log D (pH)	1.7; 3.3 or 4.2 ^b [0.84] ^c	4.25; 4.5 [#]	1.8 [#]	0.9; 2.9 [#]	1.7	2.9; 6 [#] 4.0 (pH 7.4); 4.1 (pH 6.0)	1.2; 5.2 3.9 [#]	1.9; 4.1 (mesylate); 3.8 ³	6.9 [#]
Solubility (µg/ml)	Mesylate; Aq: 190 pH 7.4: 60 pH 6.8: 190 [Calcium: Aq: 700] ^c	Aq: 4-5 mg/mL [#]	Ethanolate; Aq: 150 [#]	Aq: 15 [#] Sulfate; Aq: > 100 mg/ml pH 7.4: 70 pH 4.8: 300 pH 3.5: 60 mg/ml	Aq: very low	Mesylate; Aq: 4500 pH 7.4: very low pH 3.5: 500 pH 2.6: 4500	Aq: 1 pH 7.4: 5.3 pH 4: 6.9	Mesylate; Aq: 2220 pH 7.4: 36 pH 6.5: 73	Aq: insoluble
Intracellular Accumulation ratio's (<i>in vitro</i> in blood) ^a	3.2	1.2		0.29	1.55; 0.7-2.1	5.3	1.25; 1.7; 0.8-4.2	3.64; 4.9; 1.5-6.7	
References	103-105	22,53,106		103-105,107,108	103,109	103-105,109,110	53,103-105,109	1.53,103-105,109	

[#] Data obtained from Drugbank (<http://drugbank.ca/drugs>).

^a When coadministered with ritonavir (except nelfinavir); ritonavir: coadministered with saquinavir.

^b Conflicting results reported.

^c Fosamprenavir.

Key Pharmacokinetic Parameters of the HIV Protease Inhibitors.

Table 2

Compound	Standard Dosing Level	Metabolism and Elimination	t1/2 _b (h)	Plasma Protein Binding (%)	Ritonavir Boosting effect	Oral Bioavailability (%); [unboosted]	DME interactions (based on boosted use in the clinic)	References
Amprenavir (from fosamprenavir)	700 mg b.i.d./r 100 mg b.i.d.	hepatic 3A4, 2D6 urine:14%; feces:75 %; (unchanged:1% urine; ND in feces)	7-12	90	C _{max} 1.5 × ↑ AUC > 2× ↑ C _{trough} 4 × ↑	30-70	CYP3A	103,104
Atazanavir	300 mg q.d./r 100 mg q.d.	hepatic 3A4; Nonlinear (300-600 mg), 79% bile/13% urine; UD % dose in bile 20%, in urine 7%	6 (in HIV patients; 2 × ↓ in healthy volunteers)	86	C _{trough} 5 × ↑ AUC 3× ↑	68; pH dependent, AUC 1.7 × ↑ with food	CYP3A, UGT1A1	103,105
Darunavir	600-800 mg b.i.d./r 100 mg b.i.d.	Hepatic CYP3A4 Feces: 79.5%; urine: 13.9% Unchanged (unchanged: 41.2% in feces; 7.7 % in urine)	15	95 (AAG > ALB)	AUC 10 × ↑ ^a	82 [37] ^b	Inh.: CYP3A4, CYP2D6 Ind.: CYP2C9 CYP2C19	103,106,107
Indinavir	800 mg b.i.d./r 100 mg b.i.d.	hepatic CYP3A4; 19% and 83% recovered in urine and feces, respectively; Of this unchanged drugs accounted for 19.1% and 9.4% and in the urine and feces, respectively	2	61	AUC 2× ↑ ^a C _{min} > 4× ↑ ^a	60-65	CYP3A4 Weak 2D6 inhibitor	103,108
Lopinavir	400 mg b.i.d./r 100 mg b.i.d.	hepatic CYP3A4 10.4 % and 82% in urine and feces, respectively. Of this, 2.2 and 19.8% appeared unchanged in the urine and feces respectively	5-6	99	AUC 1.5 × ↑ ^a C _{min} 2 × ↑ ^a C _{ss} 15-20 × ↑ ^a	Not established (increased AUC and C _{max} under fed conditions however)	CYP3A4	103,109
Nelfinavir	635 mg b.i.d.	hepatic CYP3A4, 2C19, 2D6, 2C9 2% and 87% recovered in urine and feces, respectively. Of this, 22% and 1 % was unchanged in the urine and feces, respectively	1.8-3.4	99	AUC 2.5 × ↑ ^a C _{max} 1.4 × ↑ ^a	> 78	CYP3A CYP2C19	103
Ritonavir	PI + 100 mg b.i.d.		3-5	99		66-75		
Saquinavir	1 g b.i.d./r 100 mg b.i.d.	hepatic CYP3A4	13	98		< 20 (Soft Gelatin Capsule)		
Tipranavir	500 mg b.i.d./r 200 mg b.i.d.							

r = ritonavir; SGC = soft gelatin capsule; UD = unchanged drug.

^aPackage insert based on calculated ratio of boosted to unboosted AUC0-∞.

Table 3

A: HIV Protease Inhibitors as Inhibitors of ABC and SLC0 Transporters.

ABC			SLC					
Protease Inhibitor	Transporter	IC ₅₀ * or Ki** (μM)	System (Substrate)	Ref	Transporter	IC ₅₀ * or Ki** (μM)	System (Substrate)	Ref
Amprenavir	P-gp	23.1*	BBMEC (rhodamine 123)	110	OATP1B1	14.4*, 12.8**	CHO (CGamF)	21
	BCRP	181*	MDCKII (Pheophorbide A)	41	OATP1B3	19.1*, 13.1**	CHO (CGamF)	21
Atazanavir	P-gp	67.8*	MDCKII (Calcein-AM)	37	OATP1B1	1.7*, 1.5**	CHO (CGamF)	21
	BCRP	69.1*	MDCKII (Pheophorbide A)	41	OATP1B3	3*, 3**	CHO (CGamF)	21
		OATP2B1	2.2*	Caco-2 (E3S)	22			
		MDCKII (E3S)	3.6*	MDCKII (E3S)	22			
Darunavir	P-gp	33*	Not reported	111	OATP1B1	3.5*, 3.1**	CHO (CGamF)	21
		>100*	MDCKII (Calcein-AM)	37	OATP1B3	4.8*, 3.3**	CHO (CGamF)	21
		OATP2B1	29*	Caco-2 (E3S)	22			
		MDCKII (E3S)	26*	MDCKII (E3S)	22			
Indinavir	P-gp	54.6*	BBMEC (rhodamine 123)	110	OATP1B1	12.2*, 10.8**	CHO (CGamF)	21
		>100*	MDCKII (Calcein-AM)	37		5.84*	HeLa	112
		OATP1B3	12.3*, 8.5**	CHO (CGamF)	21			
		OATP2B1	3.9*, 3**	Caco-2 (E3S)	21			
		OCT1	37.6*	HEK293 (MPP)	25			
					62*	HeLa (TEA)	26	
Lopinavir	P-gp	10.3*	MDCKII (calcein-AM)	37	OATP1B1	0.5*, 0.5**	CHO (CGamF)	21
	BCRP	7.66*	MDCKII (Pheophorbide A)	41	OATP1B3	2*, 1.4**	CHO (CGamF)	21
		OATP2B1	1.7*	Caco-2 (E3S)	22			
		MDCKII (E3S)	0.72*	MDCKII (E3S)	22			
Nelfinavir	P-gp	1.7*	BBMEC (rhodamine 123)	110	OATP1B1	0.93*	HeLa (E217BG)	112
	BCRP	19.9*	MDCKII (calcein-AM)	37	OATP2B1	2.2*	Caco-2 (E3S)	22
		MDCKII (Pheophorbide A)	41	MDCKII (E3S)	22			
		HEK293 (mitoxantrone)	40	HeLa (TEA)	26			

ABC			SLC					
Protease Inhibitor	Transporter	IC ₅₀ * or K _i ** (μM)	System (Substrate)	Ref	Transporter	IC ₅₀ * or K _i ** (μM)	System (Substrate)	Ref
					OCT2	7* 13*	HEK293 (MPP) HEK293 (MPP)	25 25
Ritonavir	P-gp	3.8*	Caco-2 (digoxin)	102	OATPIB1	0.71*	HeLa (E2178G)	112
		5*	Caco-2 (digoxin)	113		0.78**	HEK293 (pitavastatin)	116
		6.7*	Caco-2 (rhodamine 123)	114		1.6*, 1.4**	CHO (CGamF)	21
		26.4*	BBMEC (rhodamine 123)	110	OATPIB3	3.6*, 2.5**	CHO (CGamF)	21
		28.2*	MDCKII (digoxin)	115	OATP2B1	6.3*, 4.8**	Caco-2 (E3S)	21
		39.6*	MDCKII (calcein-AM)	37		0.93*	Caco-2 (E3S)	22
	BCRP	19.5*	HEK293 (mitoxantrone)	40	OATPIA2	2.2*	MDCKII (E3S)	22
						<10*	HeLa (fexaofenadine)	117
						5.2*	HeLa (TEA)	26
					OCT1	14*	HEK (MPP)	25
						25*	HEK (MPP)	25
					OCT2	13.9*	HeLa (TEA)	118
					MATE1	15.4*	HeLa (metformin)	118
Saquinavir	P-gp	1.4*	BBMEC (rhodamine 123)	110	OATPIB1	1.23*	HeLa (E2178G)	112
		27.4*	MDCKII (Pheophorbide A)	41		2.1*, 1.8**	CHO (CGamF)	21
		19.5*	HEK293 (mitoxantrone)	40		1.59**	HEK293 (pitavastatin)	116
	BCRP				OATPIB3	4.1*, 2.8**	CHO (CGamF)	21
					OATPIA2	<10	HeLa (Fexofenadine)	117
					OATP2B1	5.3*, 4**	Caco-2 (E3S)	21
						3.5*	Caco-2 (E3S)	22
						4.6*	MDCKII (E3S)	22
					OCT1	8.3*	HeLa (TEA)	26
						37*	HEK293 (MPP)	25
Tipranavir				OATP2B1	0.77*	Caco-2 (E3S)	22	
					0.88*	MDCKII (E3S)	22	

SLC					
Protease Inhibitor	Transporter	IC ₅₀ * or Ki** (μM)	System (Substrate)	Ref	System (Substrate)
CGamF, cholyglycylamidofluorescein; E3S, estrone 3-sulfate; MPP, 1-methyl-4-phenylpyridinium; TEA, tetraethylammonium; E217βG, estradiol-17β-glucuronide.					

SLCO									
ABC					SLCO				
Protease Inhibitor	Transporter	K _m * (μM) or ER (PI dose)**	In vitro System	Ref	Transporter	K _m * (μM) or ER (PI dose)**	In vitro System	Ref	Ref
Amprenavir	P-gp	47*	High Five membranes MDCKII-MDR1	110					
		24.2 (10 μM)**		119					
Atazanavir									
Darunavir									
Indinavir	P-gp	0.47*	High Five membranes High Five membranes	120					
		2.1*	High Five membranes	110					
Lopinavir									
Nelfinavir	P-gp	3.6*	High Five membranes	110					
Ritonavir	P-gp	0.8*	LLC-PK1	121					
Saquinavir	P-gp	1.4*	High Five membranes LLC-PK1	110	OATPIA2	36.4*			18
		14.5*		121					
		15.4*		122					
Tipranavir									

ER, efflux ratio (B-A/A-B).

Table 4

Summary of Clinically Relevant Drug-Drug Interactions Involving HIV Protease Inhibitors with evidence for a role of drug transporters in mediating the interactions.

A. Protease Inhibitor as victim drug					
Transport Protein	Perpetrator Drug (Inhibitor/Inducer)	Victim Protease Inhibitor	Clinical Exposure changes	In Vitro Studies	
MDR1 (ABCB1, P-gp)	Rifampicin 600 mg qd	Most HIV PI	Plasma AUC $5.6 \times \downarrow$ (APV) Plasma AUC significantly $\downarrow$ (ATV) Plasma AUC $9.1 \times \downarrow$ (IDV) Plasma AUC $5.6 \times \downarrow$ (NFV) Plasma AUC $2.9 \times \downarrow$ (RTV) Plasma AUC $6.3 \times \downarrow$ (SQV) (possibly partly attributable to intestinal P-gp induction) ¹²³	HIV PI are (poor) P-gp substrates, but exact role of intestinal efflux transporters in their absorption unclear. ^{31,39,124,125}	
	Rifampicin 600 mg qd	LPV/r 800/200 mg qd 400/400 mg qd	Plasma AUC $4 \times \downarrow$ (LPV/r) ⁷⁶	LPV is an ABCB1 (but not ABCC2) substrate ^{5,6}	
	Rifampicin 600 mg qd	ATV/r 300/100 mg qd	Plasma AUC $6.7 \times \downarrow$ (ATV) and $2.9 \times \downarrow$ (RTV) (possibly partly attributable to intestinal P-gp induction; evaluated in three patients only) ¹²⁶	ATV and RTV are (poor) P-gp substrates. ³⁹	
MDR1 (ABCB1, P-gp)	Rifabutin	APV IDV NFV SQV	Inductive effects on HIV PI PK is less pronounced ($1.2-1.7 \times \downarrow$) than for rifampicin. ^{123,127}	cfr. above	
MDR1 (ABCB1, P-gp)	SJW, Ginkgo and other herbal medicines	Several HIV PI	Reduced exposure, potentially leading to therapy failure (exact contribution of efflux transporters versus drug metabolizing enzymes not clear) ¹²⁸	see Table 3, illustrating that HIV PI are substrates for efflux transporters	
MDR1 (ABCB1, P-gp)	Ketoconazole 200 bid	DRV/r 400/100 bid	Plasma DRV AUC $1.4 \times \uparrow$ ¹²⁹	DRV is a P-gp substrate, even though RTV co-administration limits the role of P-gp. ^{64,130}	
MDR1 (ABCB1, P-gp)	Ketoconazole 200-400 qd	SQV/r 400/400 bid	Plasma SQV AUC $1.4 \times \uparrow$ ¹³¹	Ketoconazole inhibits P-gp-mediated SQV transport across Caco-2 monolayers. ¹³²	
MDR1 (ABCB1, P-gp)	Etravirine	FPV700/r100 bid IDV800 tid TPV500/r200 bid ATV400 qd SQV1200 single	Plasma APV AUC $1.7 \times \uparrow$ Plasma IDV AUC $1.5 \times \downarrow$ Plasma TPV AUC $1.2 \times \uparrow$ Plasma ATV AUC $1.2 \times \downarrow$ Plasma SQV AUC $1.5 \times \downarrow$ ⁷³	Etravirine has been shown to be a potent BCRP inhibitor and inducer <i>in vitro</i> , however PI are not BCRP substrates, ⁴⁰ etravirine shows no significant P-gp inhibition, but modest induction of P-gp and MRP3 ⁷⁵	
OATP1B? (SLCO1B)	Rifabutin 150 mg qod	DRV/r 600/100 mg bid	DRV plasma AUC $1.6 \times \uparrow$ RTV plasma AUC $1.7 \times \uparrow$ Mechanism unknown but possibility of SLCO inhibition has been suggested. ¹³³	No data available on effect of rifabutin on OATP activity	
“ $\times$ ↑”: fold increase; “ $\times$ ↓”: fold decrease; “A4AXXX/rxxx” = XXX mg of AAA as a primary HIV protease inhibitor, combined with xxx mg ritonavir as a booster					

B. Protease Inhibitor as Perpetrator Drug				
Transport Protein	Victim Drug	Protease Inhibitor as Perpetrator Drug (Inhibitor/Inducer)	Clinical Exposure Changes	In Vitro Studies
MDR1	Tenofovir (TFV) disoproxil fumarate (TDF)	ATV/r; DRV/r; LPV/r; SQV/r	Plasma TFV AUC $1.1\text{--}1.4 \times \uparrow$ in combination with ATV/r; DRV/r, LPV/r, SQV/r. ^{59,134}	<ul style="list-style-type: none"> Efflux Ratio (ER) of TDF across MDCK-MDR1 is 34 (control); ER is significantly reduced to 4.3 (NFV), 4.4 (LPV, RTV); 16 (ATV); 22 (SQV); 24 (APV).⁵⁹ Limited interaction of HIV PI with transporters involved in TFV disposition in the kidney (hOAT1/3, MRP4).¹³⁵
MDR1	Fexofenadine 120 mg	LPV/r RTV	AUC $2.2 \times \uparrow$ (single RTV 100) AUC $4.0 \times \uparrow$ (single LPV/r 400/100) AUC $2.9 \times \uparrow$ (steady-state LPV/r 400/100) ¹³⁶	<ul style="list-style-type: none"> RTV $\text{IC}_{50} = 5.4 \mu\text{M}$ for P-gp-mediated fexofenadine transport across Caco-2.¹³⁷
	Fexofenadine 60 mg	RTV 200 tid – 400 bid	AUC $2.8 \times \uparrow$ (acute RTV) AUC $1.4 \times \uparrow$ (steady-state RTV) ¹³⁹	<ul style="list-style-type: none"> LPV and RTV are P-gp inhibitors (Table 3) and inducers (Table 7)
	Fexofenadine 60 mg	IDV/r 800/100 bid	AUC $5.0 \times \uparrow$ (single dose IDV/r) AUC $4.2 \times \uparrow$ (steady-state IDV/r) ⁵⁴	<ul style="list-style-type: none"> RTV causes net induction (rather than inhibition) of P-gp <i>in vivo</i> in rats – based on C_{ss}A oral BA.¹³⁸ Largest change for IDV may be explained by P-gp being an inhibitor but not an inducer
MDR1	Digoxin 0.4 mg oral	RTV200; 14d	Plasma AUC $1.2 \times \uparrow$ ¹⁴⁰	<ul style="list-style-type: none"> RTV blocks P-gp activity (Table 3)
	Digoxin 0.5 mg iv	RTV300 bid	Plasma AUC $1.9 \times \uparrow$, V_d $1.8 \times \uparrow$, Cl_{renal} $1.5 \times \downarrow$, $\text{Cl}_{\text{non-renal}}$ $2 \times \downarrow$ ¹⁴²	<ul style="list-style-type: none"> RTV ($>5 \mu\text{M}$) enhances digoxin (0.1 μM) accumulation in RBE4 cells.¹⁴¹
	Digoxin 0.4mg qd	DRV600/r100 bid	Plasma AUC $1.4 \times \uparrow$ ¹⁰⁶	<ul style="list-style-type: none"> DRV and RTV block P-gp (Table 3)
	Digoxin 0.5 mg (oral)	SQV1,000/r100 bid	Plasma AUC $1.5 \times \uparrow$ ¹⁴³	<ul style="list-style-type: none"> SQV ($>10 \mu\text{M}$) and RTV ($>5 \mu\text{M}$) enhance digoxin (0.1 μM) accumulation in RBE4 cells.¹⁴¹
	Digoxin 0.25 mg (oral)	TPV/r	Plasma AUC $1.9 \times \uparrow$ after first dose Plasma AUC unchanged and C _{max} $1.5 \times \uparrow$ at steady-state ⁷⁰	See Table 5
	Digoxin 0.5 mg (oral)	LPV400/r100 bid (14 d)	Plasma AUC $1.8 \times \uparrow$ ⁵⁵	See Table 3
MDR1	Loperamide	TPV750(r200)	Plasma AUC $2\text{--}3 \times \downarrow$; <i>in vivo</i> intestinal P-gp induction, also in presence of RTV as inhibitor. ⁶⁹	See Table 5
		RTV200	Plasma AUC $2.2 \times \uparrow$; <i>in vivo</i> intestinal P-gp inhibition, ⁶⁹ no effect on brain PD (loperamide)	See Table 3
		RTV600	Plasma AUC $3.2 \times \uparrow$; <i>in vivo</i> intestinal P-gp inhibition ⁵⁶	See Table 3

B. Protease Inhibitor as Perpetrator Drug					
Transport Protein	Victim Drug	Protease Inhibitor as Perpetrator Drug (Inhibitor/Inducer)	Clinical Exposure Changes	In Vitro Studies	
MDR1	Delavirdine	APV/600 bid	possibly partly due to intestinal P-gp induction ⁷²	See Table 5	
MDR1	Tacrolimus Sirolimus	APV/r	Case report in HIV-infected patient indicates increased tacrolimus/sirolimus half-life and trough levels, attributed to CYP and/or P-gp inhibition by APV/r ⁵⁷	See Table 3	
	Tacrolimus	DRV/r	Case report: HIV-infected kidney-transplant patient required a tacrolimus dose equal to 3.5% of usual dose. ⁵⁸	See Table 3	
	Sildenafil	DRV/r 400/100 bid	Plasma AUC $4 \times \uparrow$; possibly due to P-gp inhibition (or OATP inhibition) ¹⁴⁴	See Table 3	
	Ketoconazole 200 bid	DRV/r 400/100 bid	Plasma AUC $3.1 \times \uparrow$; possibly due to P-gp inhibition (or OATP inhibition) ¹³³	See Table 3	
	Ketoconazole 200 qd	RTV	Plasma AUC $3.4 \times \uparrow$; possibly due to P-gp inhibition (or OATP inhibition) ¹⁴⁵	See Table 3	
	Ketoconazole 200 single dose	LPV/r 400/100 bid	Plasma AUC $3.0 \times \uparrow$; possibly due to P-gp inhibition (or OATP inhibition) ¹⁰⁹	See Table 3	
	Ketoconazole 200 qd	FPV/r 700/100 bid	Plasma AUC $2.7 \times \uparrow$; possibly due to P-gp inhibition (or OATP inhibition) ¹⁰⁴	See Table 3	
OATP/BCRP	Atorvastatin	LPV/r TPV/r SQV/r (400/400 bid) DRV/r (300/100 bid)	AUC $5.9 \times \uparrow$ (TPV/r) AUC $9.4 \times \uparrow$ (TPV/r) ⁶² AUC $3.4 \times \uparrow$ (SQV/r) ¹⁴⁶ AUC $4.0 \times \uparrow$ (DRV/r) ^{62,147}	<ul style="list-style-type: none"> Atorvastatin is an OATP1B1 and BCRP substrate^{148,149} HIV PI are OATP and BCRP inhibitors^{41,150,151} 	
OATP1B1/BCRP	Rosuvastatin	TPV/r LPV/r ATV/r	AUC $1.4 \times \uparrow$ (TPV/r) ⁶² AUC $2.1 \times \uparrow$ (LPV/r); $t_{1/2}$ not affected ¹³⁴ AUC $3.1 \times \uparrow$ (APV/r) ¹⁵²	<ul style="list-style-type: none"> Rosuvastatin is an OATP1B1 and BCRP substrate^{148,149} LPV, TPV, ATV and RTV are OATP and BCRP inhibitors^{41,150,151} 	
OATP1B1 MRP2	Pravastatin 40 mg qd	DRV/r 600/100bid	Plasma AUC $1.8 \times \uparrow$ ¹⁰⁶	See Table 3 ¹⁵³	
OATP/MDR1	Fexofenadine	NLF 1250 bid (1wk)	Fexofenadine C _{max} $1.3 \times \downarrow$, $t_{1/2}$ $1.3 \times \downarrow$; possibly due to intestinal P-gp and hepatic OATP induction ⁷¹	See Table 5	
OATP2B1?	Elvucitabine 20 mg	RTV 300 (single dose)	Elvucitabine AUC $1.3 \times \downarrow$ and C _{max} $1.7 \times \downarrow$; possibly due to inhibition of intestinal influx transporters ⁶³	See Table 3 for effect of RTV on OATP activity	
Uptake transporters?	Etravirine	DRV/r (600/100 bid)	100 bid: plasma AUC $1.6 \times \downarrow$ 200 bid: plasma AUC $1.8 \times \uparrow$ ^{52,154}	Etravirine is not a substrate for P-gp, BCRP or MRP1-3. ⁷⁵ The role of uptake transporters has not been investigated.	
	Etravirine	TPV/r (500/200 bid)	Plasma AUC $4.2 \times \uparrow$ ⁷³	See Table 5	

“ $\times$ $\uparrow$ ”: fold increase; “ $\times$ $\downarrow$ ”: fold decrease; “AAA mg of AAA as a primary HIV protease inhibitor, combined with xxx mg ritonavir as a booster”

Table 5

In vitro Induction Data With HIV Protease Inhibitors

Transporter	HIV PI	Model System (marker): Effect (conc)	Reference
MDR1	APV	T84 (0.1 μ M digoxin ER): ER doubled (10 μ M; 72h)	96,156
		T84 (mRNA): 5 $\times$ $\uparrow$ (10 μ M; 72h)	
		LS180 (mRNA): 17 $\times$ $\uparrow$ (10 μ M; 96h)	
		LS180V (protein): 2.5 $\times$ $\uparrow$ (30 μ M; 3 d)	
	ATV	LS180V (Rh123 uptake): 55% $\downarrow$ (30 μ M; 3 d)	96,157,158
		hCMC/D3 cells (protein): 2.5 $\times$ $\uparrow$ (10 μ M; 3d)	
		LS180 (mRNA): 5 $\times$ $\uparrow$ (10 μ M; 96h)	
		LS180 (mRNA): 3.8 $\times$ $\uparrow$ (10 μ M; 1wk)	
	DRV	No significant P-gp induction	34
	IDV		96,157,158
	LPV	LS-180V (protein/mRNA): 3 $\times$ $\uparrow$ (30 μ M 72h)	96,157-159
		LS-180V (Rh123 uptake): 50% $\downarrow$ (30 μ M 72h)	
		LS180 (mRNA): 12 $\times$ $\uparrow$ (10 μ M; 96h)	
	NFV	Cultured Hepatocytes (mRNA): 4-6 $\times$ $\uparrow$ (10-25 μ M) Cytotrophoblast culture (Rh123 uptake): 23% $\downarrow$ (3 μ g/ml; 24h)	67,96,160
		LS180 (mRNA): EC50 = 1.2 μ M (96h); LS180 (mRNA): 7 $\times$ $\uparrow$ (10 μ M; 96h)	
	RTV	Human hepatocytes (mRNA): 9-10 $\times$ $\uparrow$ (10-25 μ M)	67,96,97,158,161
		LS-180V cells (protein): 6 $\times$ $\uparrow$ (1-100 μ M; 3d)	
		LS-180V (Rh123 uptake): 50% $\downarrow$ (>10 μ M; 3d)	
		hCMC/D3 cells (protein): 2 $\times$ $\uparrow$ (10 μ M; 3d)	
		LS180 (mRNA): EC50 = 1.7 μ M (96h); LS180 (mRNA): 12 $\times$ $\uparrow$ (10 μ M; 96h)	
	SQV	LS180 (mRNA): 5.7 $\times$ $\uparrow$ (10 μ M; 1wk)	34,96,160
		Cytotrophoblast culture (protein): 2 $\times$ $\uparrow$ (1 μ g/ml; 24h)	
		Cytotrophoblast culture (Rh123 uptake): 18% $\downarrow$ (1 μ g/ml; 24h)	
		LS180 (mRNA): 5 $\times$ $\uparrow$ (10 μ M; 96h)	
	TPV	LS180 (mRNA): 10 $\times$ $\uparrow$ (10 μ M; 96h)	96
MRP1	RTV	LS-180V cells (protein): 3 $\times$ $\uparrow$ (1-100 μ M; 3d)	97
		LS-180V (CBF uptake): 30% $\downarrow$ (30 μ M; 3d)	
	SQV	LS180 (mRNA): 2.3 $\times$ $\uparrow$ (10 μ M; 1wk)	34
MRP2	NFV	Human hepatocytes (mRNA): 2-4 $\times$ $\uparrow$ (10-25 μ M)	67
		Human hepatocytes (mRNA): 5-6 $\times$ $\uparrow$ (10-25 μ M)	
	RTV	LS180 (mRNA): 4.5 $\times$ $\uparrow$ (10 μ M; 1wk)	34
MRP3	SQV	LS180 (mRNA): 2 $\times$ $\uparrow$ (10 μ M; 1wk)	34
MRP4	SQV	LS180 (mRNA): 1.8 $\times$ $\uparrow$ (10 μ M; 1wk)	34
MRP5	SQV	LS180 (mRNA): 3.8 $\times$ $\uparrow$ (10 μ M; 1wk)	34
BCRP	NFV	Human hepatocytes (mRNA): < 2 $\times$ $\uparrow$ (10-25 μ M)	67

Transporter	HIV PI	Model System (marker): Effect (conc)	Reference
	RTV	Human hepatocytes (mRNA): 2-3× ↑ (10-25 μM)	67
	SQV	LS180 (mRNA): 4.1× ↑ (10μM; 1wk)	34
OATP1B1	NFV	Hepatocytes (mRNA): 2-3× ↑ (10-25 μM)	67
	RTV	Hepatocytes (mRNA): 2× ↑ (10-25 μM)	67
	SQV	LS180 (mRNA): 4.6× ↑ (10μM; 1wk)	34
OATP1B3	NFV	Human hepatocytes (mRNA): 2-5× ↑ (10-25 μM)	67
	RTV	Human hepatocytes (mRNA): 3-4× ↑ (10-25 μM)	67
OATP2B1	DRV	LS180 (mRNA): 1.9× ↑ (10μM; 1wk)	34
	SQV	LS180 (mRNA): 1.8× ↑ (10μM; 1wk)	34

ER, Efflux ratio (B-A/A-B).

Table 6
Clinically Relevant Examples of Transporter-mediated Interactions Between HIV Protease Inhibitors and Endogenous Compounds.

Endogenous Compound	Transport Protein	Protease Inhibitor	In Vitro Studies	Clinical Relevance
Bile salts	NTCP BSEP	RTV, SQV	Inhibition of bile acid transport ⁷⁸	Increased serum bile acids; Increased hepatocyte bile acids; Increased risk for hepatotoxicity
Palmitate	CD36 and CPT1 fatty acid transporters	LPV/r and DRV/r (not ATV/r)	Inhibition of palmitate uptake in cultured skeletal muscle cells (myotubes) ⁸²	Dyslipidaemia, insulin resistance
Bilirubin	OATP1B1	ATV, IDV	Potent inhibition of OATP1B activity by HIV protease inhibitors causing increased incidence of hyperbilirubinemia and jaundice ^{47,81}	Increased serum bilirubin levels associated with the use of specific protease inhibitors. ⁸⁰